1 HEMOSTASIS
1.1 FORMATION OF FIBRIN CLOT (CLOTTING CASCADE)
1.1.1 EXTRINSIC PATHWAY OF FIBRIN CLOT FORMATION
1.1.2 INTRINSIC PATHWAY OF FIBRIN CLOT FORMATION
1.1.3 COMMON PATHWAY OF FIBRIN CLOT FORMATION
1.2 CELL SURFACE INTERACTIONS AT THE VASCULAR WALL
1.2.1 PECAM1 INTERACTIONS
1.2.2 BASIGIN INTERACTIONS
1.2.3 TIE2 SIGNALING
1.3 PLATELET HOMEOSTASIS
1.3.1 NITRIC OXIDE STIMULATES GUANYLATE CYCLASE
1.3.1.1 CGMP EFFECTS
1.3.2 PROSTACYCLIN SIGNALLING THROUGH PROSTACYCLIN RECEPTOR
1.3.3 PLATELET CALCIUM HOMEOSTASIS
1.3.3.1 ELEVATION OF CYTOSOLIC CA2+ LEVELS
1.3.3.2 REDUCTION OF CYTOSOLIC CA++ LEVELS
1.3.4 PLATELET SENSITIZATION BY LDL
1.4 DISSOLUTION OF FIBRIN CLOT
1.5 PLATELET ADHESION TO EXPOSED COLLAGEN
1.6 "PLATELET ACTIVATION, SIGNALING AND AGGREGATION"
1.6.1 EFFECTS OF PIP2 HYDROLYSIS
1.6.1.1 ARACHIDONATE PRODUCTION FROM DAG
1.6.2 GPVI-MEDIATED ACTIVATION CASCADE
1.6.3 SIGNAL AMPLIFICATION
1.6.3.1 ADP SIGNALLING THROUGH P2Y PURINOCEPTOR 12
1.6.3.2 ADP SIGNALLING THROUGH P2Y PURINOCEPTOR 1
1.6.3.3 THROMBOXANE SIGNALLING THROUGH TP RECEPTOR
1.6.4 GP1B-IX-V ACTIVATION SIGNALLING
1.6.5 THROMBIN SIGNALLING THROUGH PROTEINASE ACTIVATED RECEPTORS (PARS)
1.6.6 RESPONSE TO ELEVATED PLATELET CYTOSOLIC CA2+
1.6.6.1 DISINHIBITION OF SNARE FORMATION
1.6.6.2 PLATELET DEGRANULATION
1.6.7 PLATELET AGGREGATION (PLUG FORMATION)
1.6.7.1 INTEGRIN ALPHAIIB BETA3 SIGNALING
1.6.7.1.1 GRB2:SOS PROVIDES LINKAGE TO MAPK SIGNALING FOR INTEGRINS
1.6.7.1.2 P130CAS LINKAGE TO MAPK SIGNALING FOR INTEGRINS
1.6.7.2 ADRENALINE SIGNALLING THROUGH ALPHA-2 ADRENERGIC RECEPTOR
1.7 FACTORS INVOLVED IN MEGAKARYOCYTE DEVELOPMENT AND PLATELET PRODUCTION
1.7.1 KINESINS
2 NEURONAL SYSTEM
2.1 TRANSMISSION ACROSS ELECTRICAL SYNAPSES
2.1.1 ELECTRIC TRANSMISSION ACROSS GAP JUNCTIONS
2.2 TRANSMISSION ACROSS CHEMICAL SYNAPSES
2.2.1 PRESYNAPTIC DEPOLARIZATION AND CALCIUM CHANNEL OPENING
2.2.2 NEUROTRANSMITTER RELEASE CYCLE
2.2.2.1 SEROTONIN NEUROTRANSMITTER RELEASE CYCLE
2.2.2.2 NOREPINEPHRINE NEUROTRANSMITTER RELEASE CYCLE
2.2.2.3 GLUTAMATE NEUROTRANSMITTER RELEASE CYCLE
2.2.2.4 DOPAMINE NEUROTRANSMITTER RELEASE CYCLE
2.2.2.5 ACETYLCHOLINE NEUROTRANSMITTER RELEASE CYCLE
2.2.2.6 "GABA SYNTHESIS, RELEASE, REUPTAKE AND DEGRADATION"
2.2.2.6.1 GABA SYNTHESIS
2.2.2.6.2 REUPTAKE OF GABA
2.2.2.6.3 DEGRADATION OF GABA
2.2.3 NEUROTRANSMITTER CLEARANCE
2.2.3.1 DOPAMINE CLEARANCE FROM THE SYNAPTIC CLEFT
2.2.3.1.1 ENZYMATIC DEGRADATION OF DOPAMINE BY COMT
2.2.3.1.2 ENZYMATIC DEGRADATION OF DOPAMINE BY MONOAMINE OXIDASE
2.2.3.2 SEROTONIN CLEARANCE FROM THE SYNAPTIC CLEFT
2.2.3.2.1 METABOLISM OF SEROTONIN
2.2.4 NEUROTRANSMITTER UPTAKE AND METABOLISM IN GLIAL CELLS
2.2.4.1 ASTROCYTIC GLUTAMATE-GLUTAMINE UPTAKE AND METABOLISM
2.2.5 NEUROTRANSMITTER RECEPTORS AND POSTSYNAPTIC SIGNAL TRANSMISSION
2.2.5.1 ACETYLCHOLINE BINDING AND DOWNSTREAM EVENTS
2.2.5.1.1 ACTIVATION OF NICOTINIC ACETYLCHOLINE RECEPTORS
2.2.5.1.1.1 PRESYNAPTIC NICOTINIC ACETYLCHOLINE RECEPTORS
2.2.5.1.1.1.1 HIGHLY SODIUM PERMEABLE ACETYLCHOLINE NICOTINIC RECEPTORS
2.2.5.1.1.1.2 HIGHLY CALCIUM PERMEABLE NICOTINIC ACETYLCHOLINE RECEPTORS
2.2.5.1.1.2 POSTSYNAPTIC NICOTINIC ACETYLCHOLINE RECEPTORS
2.2.5.1.1.2.1 HIGHLY SODIUM PERMEABLE ACETYLCHOLINE NICOTINIC RECEPTORS
2.2.5.1.1.2.2 HIGHLY CALCIUM PERMEABLE POSTSYNAPTIC NICOTINIC ACETYLCHOLINE RECEPTORS
2.2.5.2 "GLUTAMATE BINDING, ACTIVATION OF AMPA RECEPTORS AND SYNAPTIC PLASTICITY"
2.2.5.2.1 ACTIVATION OF AMPA RECEPTORS
2.2.5.2.2 TRAFFICKING OF AMPA RECEPTORS
2.2.5.2.2.1 TRAFFICKING OF GLUR2-CONTAINING AMPA RECEPTORS
2.2.5.3 ACTIVATION OF NMDA RECEPTORS AND POSTSYNAPTIC EVENTS
2.2.5.3.1 POST NMDA RECEPTOR ACTIVATION EVENTS
2.2.5.3.1.1 CREB1 PHOSPHORYLATION THROUGH THE ACTIVATION OF ADENYLATE CYCLASE
2.2.5.3.1.2 CREB1 PHOSPHORYLATION THROUGH THE ACTIVATION OF CAMKII/CAMKK/CAMKIV CASCASDE
2.2.5.3.1.3 CREB1 PHOSPHORYLATION THROUGH NMDA RECEPTOR-MEDIATED ACTIVATION OF RAS SIGNALING
2.2.5.3.1.3.1 RAS ACTIVATION UPON CA2+ INFLUX THROUGH NMDA RECEPTOR
2.2.5.3.1.3.2 RSK ACTIVATION
2.2.5.3.1.4 ACTIVATION OF RAC1 DOWNSTREAM OF NMDARS
2.2.5.3.1.5 ACTIVATION OF AMPK DOWNSTREAM OF NMDARS
2.2.5.3.1.6 LONG-TERM POTENTIATION
2.2.5.3.2 "UNBLOCKING OF NMDA RECEPTORS, GLUTAMATE BINDING AND ACTIVATION"
2.2.5.3.3 NEGATIVE REGULATION OF NMDA RECEPTOR-MEDIATED NEURONAL TRANSMISSION
2.2.5.4 ACTIVATION OF KAINATE RECEPTORS UPON GLUTAMATE BINDING
2.2.5.4.1 IONOTROPIC ACTIVITY OF KAINATE RECEPTORS
2.2.5.4.1.1 ACTIVATION OF NA-PERMEABLE KAINATE RECEPTORS
2.2.5.4.1.2 ACTIVATION OF CA-PERMEABLE KAINATE RECEPTOR
2.2.5.4.2 PRESYNAPTIC FUNCTION OF KAINATE RECEPTORS
2.2.5.5 GABA RECEPTOR ACTIVATION
2.2.5.5.1 GABA A RECEPTOR ACTIVATION
2.2.5.5.2 GABA A (RHO) RECEPTOR ACTIVATION
2.2.5.5.3 GABA B RECEPTOR ACTIVATION
2.2.5.5.3.1 ACTIVATION OF GABAB RECEPTORS
2.2.5.5.3.1.1 INHIBITION OF ADENYLATE CYCLASE PATHWAY
2.2.5.5.3.1.1.1 ADENYLATE CYCLASE INHIBITORY PATHWAY
2.2.5.5.3.1.2 INHIBITION  OF VOLTAGE GATED CA2+ CHANNELS VIA GBETA/GAMMA SUBUNITS
2.3 POTASSIUM CHANNELS
2.3.1 CA2+ ACTIVATED K+ CHANNELS
2.3.2 HCN CHANNELS
2.3.3 INWARDLY RECTIFYING K+ CHANNELS
2.3.3.1 ATP SENSITIVE POTASSIUM CHANNELS
2.3.3.2 CLASSICAL KIR CHANNELS
2.3.3.3 G PROTEIN GATED POTASSIUM CHANNELS
2.3.3.3.1 ACTIVATION OF G PROTEIN GATED POTASSIUM CHANNELS
2.3.3.4 POTASSIUM TRANSPORT CHANNELS
2.3.4 VOLTAGE GATED POTASSIUM CHANNELS
2.3.5 TANDEM PORE DOMAIN POTASSIUM CHANNELS
2.3.5.1 TANDEM PORE DOMAIN HALOTHANE-INHIBITED K+ CHANNEL (THIK)
2.3.5.2 TANDEM OF PORE DOMAIN IN A WEAK INWARDLY RECTIFYING K+ CHANNELS (TWIK)
2.3.5.3 TWIK-RELEATED ACID-SENSITIVE K+ CHANNEL (TASK)
2.3.5.4 TWIK-RELATED SPINAL CORD K+ CHANNEL (TRESK)
2.3.5.5 TWIK-RELATED ALKALINE PH ACTIVATED K+ CHANNEL (TALK)
2.3.5.6 TWIK RELATED POTASSIUM CHANNEL (TREK)
2.4 PROTEIN-PROTEIN INTERACTIONS AT SYNAPSES
2.4.1 RECEPTOR-TYPE TYROSINE-PROTEIN PHOSPHATASES
2.4.2 NEUREXINS AND NEUROLIGINS
2.4.3 SYNAPTIC ADHESION-LIKE MOLECULES
3 DEVELOPMENTAL BIOLOGY
3.1 SIGNALING BY NODAL
3.1.1 REGULATION OF SIGNALING BY NODAL
3.2 REGULATION OF BETA-CELL DEVELOPMENT
3.2.1 REGULATION OF GENE EXPRESSION IN LATE STAGE (BRANCHING MORPHOGENESIS) PANCREATIC BUD PRECURSOR CELLS
3.2.2 REGULATION OF GENE EXPRESSION IN BETA CELLS
3.2.2.1 AKT-MEDIATED INACTIVATION OF FOXO1A
3.2.3 REGULATION OF GENE EXPRESSION IN ENDOCRINE-COMMITTED (NEUROG3+) PROGENITOR CELLS
3.2.4 REGULATION OF GENE EXPRESSION IN EARLY PANCREATIC PRECURSOR CELLS
3.3 TRANSCRIPTIONAL REGULATION OF WHITE ADIPOCYTE DIFFERENTIATION
3.4 AXON GUIDANCE
3.4.1 EPH-EPHRIN SIGNALING
3.4.1.1 EPHB-MEDIATED FORWARD SIGNALING
3.4.1.2 EPHA-MEDIATED GROWTH CONE COLLAPSE
3.4.1.3 EPHRIN SIGNALING
3.4.1.4 EPH-EPHRIN MEDIATED REPULSION OF CELLS
3.4.2 NETRIN-1 SIGNALING
3.4.2.1 DSCAM INTERACTIONS
3.4.2.2 DCC MEDIATED ATTRACTIVE SIGNALING
3.4.2.3 NETRIN MEDIATED REPULSION SIGNALS
3.4.2.4 ROLE OF SECOND MESSENGERS IN NETRIN-1 SIGNALING
3.4.3 SEMAPHORIN INTERACTIONS
3.4.3.1 SEMA3A PAK DEPENDENT AXON REPULSION
3.4.3.2 SEMA3A-PLEXIN REPULSION SIGNALING BY INHIBITING INTEGRIN ADHESION
3.4.3.3 CRMPS IN SEMA3A SIGNALING
3.4.3.4 SEMA4D IN SEMAPHORIN SIGNALING
3.4.3.4.1 SEMA4D MEDIATED INHIBITION OF CELL ATTACHMENT AND MIGRATION
3.4.3.4.2 SEMA4D INDUCED CELL MIGRATION AND GROWTH-CONE COLLAPSE
3.4.3.5 OTHER SEMAPHORIN INTERACTIONS
3.4.4 L1CAM INTERACTIONS
3.4.4.1 RECYCLING PATHWAY OF L1
3.4.4.2 INTERACTION BETWEEN L1 AND ANKYRINS
3.4.4.3 SIGNAL TRANSDUCTION BY L1
3.4.4.4 NRCAM INTERACTIONS
3.4.4.5 CHL1 INTERACTIONS
3.4.4.6 NEUROFASCIN INTERACTIONS
3.4.5 NCAM SIGNALING FOR NEURITE OUT-GROWTH
3.4.5.1 NCAM1 INTERACTIONS
3.4.6 SIGNALING BY ROBO RECEPTORS
3.4.6.1 ACTIVATION OF RAC1
3.4.6.2 REGULATION OF COMMISSURAL AXON PATHFINDING BY SLIT AND ROBO
3.4.6.3 INACTIVATION OF CDC42 AND RAC1
3.4.6.4 ROLE OF ABL IN ROBO-SLIT SIGNALING
3.4.6.5 SLIT2:ROBO1 INCREASES RHOA ACTIVITY
3.4.6.6 REGULATION OF CORTICAL DENDRITE BRANCHING
3.4.6.7 REGULATION OF EXPRESSION OF SLITS AND ROBOS
3.4.6.8 ROBO RECEPTORS BIND AKAP5
3.4.7 RET SIGNALING
3.4.8 REELIN SIGNALLING PATHWAY
3.5 TRANSCRIPTIONAL REGULATION OF PLURIPOTENT STEM CELLS
3.5.1 "POU5F1 (OCT4), SOX2, NANOG REPRESS GENES RELATED TO DIFFERENTIATION"
3.5.2 "POU5F1 (OCT4), SOX2, NANOG ACTIVATE GENES RELATED TO PROLIFERATION"
3.6 MYOGENESIS
3.6.1 CDO IN MYOGENESIS
3.7 ACTIVATION OF HOX GENES DURING DIFFERENTIATION
3.7.1 ACTIVATION OF ANTERIOR HOX GENES IN HINDBRAIN DEVELOPMENT DURING EARLY EMBRYOGENESIS
3.8 LGI-ADAM INTERACTIONS
3.9 KERATINIZATION
3.9.1 FORMATION OF THE CORNIFIED ENVELOPE
4 METABOLISM
4.1 MITOCHONDRIAL IRON-SULFUR CLUSTER BIOGENESIS
4.1.1 ELECTRON TRANSPORT FROM NADPH TO FERREDOXIN
4.2 THE CITRIC ACID (TCA) CYCLE AND RESPIRATORY ELECTRON TRANSPORT
4.2.1 "RESPIRATORY ELECTRON TRANSPORT, ATP SYNTHESIS BY CHEMIOSMOTIC COUPLING, AND HEAT PRODUCTION BY UNCOUPLING PROTEINS."
4.2.1.1 FORMATION OF ATP BY CHEMIOSMOTIC COUPLING
4.2.1.2 MITOCHONDRIAL UNCOUPLING PROTEINS
4.2.1.2.1 THE FATTY ACID CYCLING MODEL
4.2.1.2.2 THE PROTON BUFFERING MODEL
4.2.1.3 RESPIRATORY ELECTRON TRANSPORT
4.2.1.3.1 COMPLEX I BIOGENESIS
4.2.2 PYRUVATE METABOLISM AND CITRIC ACID (TCA) CYCLE
4.2.2.1 PYRUVATE METABOLISM
4.2.2.1.1 REGULATION OF PYRUVATE DEHYDROGENASE (PDH) COMPLEX
4.2.2.2 CITRIC ACID CYCLE (TCA CYCLE)
4.2.2.3 INTERCONVERSION OF 2-OXOGLUTARATE AND 2-HYDROXYGLUTARATE
4.3 REVERSIBLE HYDRATION OF CARBON DIOXIDE
4.4 INOSITOL PHOSPHATE METABOLISM
4.4.2 SYNTHESIS OF PYROPHOSPHATES IN THE CYTOSOL
4.4.4 "SYNTHESIS OF IP2, IP, AND INS IN THE CYTOSOL"
4.4.6 SYNTHESIS OF IPS IN THE NUCLEUS
4.4.9 SYNTHESIS OF IP3 AND IP4 IN THE CYTOSOL
4.4.12 SYNTHESIS OF IPS IN THE ER LUMEN
4.5 METABOLISM OF NUCLEOTIDES
4.5.1 INTERCONVERSION OF NUCLEOTIDE DI- AND TRIPHOSPHATES
4.5.2 NUCLEOBASE CATABOLISM
4.5.2.1 PYRIMIDINE CATABOLISM
4.5.2.2 PURINE CATABOLISM
4.5.2.2.1 PHOSPHATE BOND HYDROLYSIS BY NUDT PROTEINS
4.5.2.3 PHOSPHATE BOND HYDROLYSIS BY NTPDASE PROTEINS
4.5.3 NUCLEOBASE BIOSYNTHESIS
4.5.3.1 PYRIMIDINE BIOSYNTHESIS
4.5.3.2 PURINE RIBONUCLEOSIDE MONOPHOSPHATE BIOSYNTHESIS
4.5.4 NUCLEOTIDE SALVAGE
4.5.4.1 PYRIMIDINE SALVAGE
4.5.4.2 PURINE SALVAGE
4.6 INTEGRATION OF ENERGY METABOLISM
4.6.1 PKA-MEDIATED PHOSPHORYLATION OF KEY METABOLIC FACTORS
4.6.2 GLUCAGON SIGNALING IN METABOLIC REGULATION
4.6.2.1 PKA ACTIVATION IN GLUCAGON SIGNALLING
4.6.3 AMPK INHIBITS CHREBP TRANSCRIPTIONAL ACTIVATION ACTIVITY
4.6.4 INSULIN EFFECTS INCREASED SYNTHESIS OF XYLULOSE-5-PHOSPHATE
4.6.5 CHREBP ACTIVATES METABOLIC GENE EXPRESSION
4.6.6 PP2A-MEDIATED DEPHOSPHORYLATION OF KEY METABOLIC FACTORS
4.6.7 REGULATION OF INSULIN SECRETION
4.6.7.1 GLUCAGON-LIKE PEPTIDE-1 (GLP1) REGULATES INSULIN SECRETION
4.6.7.2 ACETYLCHOLINE REGULATES INSULIN SECRETION
4.6.7.3 "ADRENALINE,NORADRENALINE INHIBITS INSULIN SECRETION"
4.6.7.4 FREE FATTY ACIDS REGULATE INSULIN SECRETION
4.6.7.4.1 FATTY ACIDS BOUND TO GPR40 (FFAR1) REGULATE INSULIN SECRETION
4.7 METABOLISM OF PORPHYRINS
4.7.1 HEME BIOSYNTHESIS
4.7.2 HEME DEGRADATION
4.8 METABOLISM OF VITAMINS AND COFACTORS
4.8.1 METABOLISM OF WATER-SOLUBLE VITAMINS AND COFACTORS
4.8.1.1 "COBALAMIN (CBL, VITAMIN B12) TRANSPORT AND METABOLISM"
4.8.1.2 METABOLISM OF FOLATE AND PTERINES
4.8.1.3 BIOTIN TRANSPORT AND METABOLISM
4.8.1.4 NICOTINATE METABOLISM
4.8.1.4.1 NICOTINAMIDE SALVAGING
4.8.1.5 VITAMIN B1 (THIAMIN) METABOLISM
4.8.1.6 VITAMIN C (ASCORBATE) METABOLISM
4.8.1.7 VITAMIN B2 (RIBOFLAVIN) METABOLISM
4.8.1.8 VITAMIN B5 (PANTOTHENATE) METABOLISM
4.8.1.8.1 COENZYME A BIOSYNTHESIS
4.8.1.9 MOLYBDENUM COFACTOR BIOSYNTHESIS
4.8.1.10 VITAMINS B6 ACTIVATION TO PYRIDOXAL PHOSPHATE
4.8.2 METABOLISM OF FAT-SOLUBLE VITAMINS
4.8.2.1 METABOLISM OF VITAMIN K
4.8.2.2 VITAMIN E
4.8.2.3 RETINOID METABOLISM AND TRANSPORT
4.8.3 METABOLISM OF COFACTORS
4.8.3.1 "TETRAHYDROBIOPTERIN (BH4) SYNTHESIS, RECYCLING, SALVAGE AND REGULATION"
4.8.3.2 UBIQUINOL BIOSYNTHESIS
4.8.3.3 NADPH REGENERATION
4.9 METABOLISM OF NITRIC OXIDE
4.9.1 ENOS ACTIVATION AND REGULATION
4.9.1.1 ENOS ACTIVATION
4.9.1.2 NOSTRIN MEDIATED ENOS TRAFFICKING
4.9.1.3 NOSIP MEDIATED ENOS TRAFFICKING
4.1 BIOLOGICAL OXIDATIONS
4.10.1 PHASE II - CONJUGATION OF COMPOUNDS
4.10.1.1 METHYLATION
4.10.1.2 ACETYLATION
4.10.1.3 CYTOSOLIC SULFONATION OF SMALL MOLECULES
4.10.1.3.1 TRANSPORT AND SYNTHESIS OF PAPS
4.10.1.4 AMINO ACID CONJUGATION
4.10.1.4.1 CONJUGATION OF CARBOXYLIC ACIDS
4.10.1.4.1.1 CONJUGATION OF SALICYLATE WITH GLYCINE
4.10.1.4.1.2 CONJUGATION OF BENZOATE WITH GLYCINE
4.10.1.4.1.3 CONJUGATION OF PHENYLACETATE WITH GLUTAMINE
4.10.1.5 GLUCURONIDATION
4.10.1.5.1 "FORMATION OF THE ACTIVE COFACTOR, UDP-GLUCURONATE"
4.10.1.6 GLUTATHIONE CONJUGATION
4.10.1.6.1 GLUTATHIONE SYNTHESIS AND RECYCLING
4.10.2 PHASE I - FUNCTIONALIZATION OF COMPOUNDS
4.10.2.1 AMINE OXIDASE REACTIONS
4.10.2.1.1 BIOGENIC AMINES ARE OXIDATIVELY DEAMINATED TO ALDEHYDES BY MAOA AND MAOB
4.10.2.1.2 PAOS OXIDISE POLYAMINES TO AMINES
4.10.2.2 COX REACTIONS
4.10.2.3 CYTOCHROME P450 - ARRANGED BY SUBSTRATE TYPE
4.10.2.3.1 VITAMINS
4.10.2.3.2 FATTY ACIDS
4.10.2.3.3 MISCELLANEOUS SUBSTRATES
4.10.2.3.4 ENDOGENOUS STEROLS
4.10.2.3.4.1 STEROLS ARE 12-HYDROXYLATED BY CYP8B1
4.10.2.3.5 EICOSANOIDS
4.10.2.3.6 XENOBIOTICS
4.10.2.3.6.1 AROMATIC AMINES CAN BE N-HYDROXYLATED OR N-DEALKYLATED BY CYP1A2
4.10.2.3.6.2 CYP2E1 REACTIONS
4.10.2.4 FMO OXIDISES NUCLEOPHILES
4.10.2.5 ETHANOL OXIDATION
4.10.2.6 ARYL HYDROCARBON RECEPTOR SIGNALLING
4.10.3 AFLATOXIN ACTIVATION AND DETOXIFICATION
4.11 ABACAVIR TRANSPORT AND METABOLISM
4.11.1 ABACAVIR TRANSMEMBRANE TRANSPORT
4.11.2 ABACAVIR METABOLISM
4.12 CYTOSOLIC IRON-SULFUR CLUSTER ASSEMBLY
4.13 METABOLISM OF LIPIDS
4.13.1 PHOSPHOLIPID METABOLISM
4.13.1.1 GLYCEROPHOSPHOLIPID BIOSYNTHESIS
4.13.1.1.1 ACYL CHAIN REMODELLING OF PC
4.13.1.1.2 ACYL CHAIN REMODELING OF CL
4.13.1.1.3 ACYL CHAIN REMODELLING OF PS
4.13.1.1.4 ACYL CHAIN REMODELLING OF PE
4.13.1.1.5 ACYL CHAIN REMODELING OF DAG AND TAG
4.13.1.1.6 ACYL CHAIN REMODELLING OF PI
4.13.1.1.7 ACYL CHAIN REMODELLING OF PG
4.13.1.1.8 SYNTHESIS OF CL
4.13.1.1.9 SYNTHESIS OF PS
4.13.1.1.10 HYDROLYSIS OF LPC
4.13.1.1.11 SYNTHESIS OF PG
4.13.1.1.12 HYDROLYSIS OF LPE
4.13.1.1.13 SYNTHESIS OF PA
4.13.1.1.15 SYNTHESIS OF PC
4.13.1.1.16 PI AND PC TRANSPORT BETWEEN ER AND GOLGI MEMBRANES
4.13.1.1.17 SYNTHESIS OF PE
4.13.1.1.18 SYNTHESIS OF PI
4.13.1.2 PI METABOLISM
4.13.1.2.1 PI AND PC TRANSPORT BETWEEN ER AND GOLGI MEMBRANES
4.13.1.2.2 SYNTHESIS OF PIPS AT THE ER MEMBRANE
4.13.1.2.3 SYNTHESIS OF PIPS AT THE PLASMA MEMBRANE
4.13.1.2.7 SYNTHESIS OF PIPS AT THE GOLGI MEMBRANE
4.13.1.2.8 SYNTHESIS OF PIPS AT THE EARLY ENDOSOME MEMBRANE
4.13.1.2.9 SYNTHESIS OF PIPS AT THE LATE ENDOSOME MEMBRANE
4.13.1.2.12 GLYCEROPHOSPHOLIPID CATABOLISM
4.13.1.2.13 SYNTHESIS OF PIPS IN THE NUCLEUS
4.13.2 REGULATION OF LIPID METABOLISM BY PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA (PPARALPHA)
4.13.2.1 PPARA ACTIVATES GENE EXPRESSION
4.13.3 SPHINGOLIPID METABOLISM
4.13.3.1 SPHINGOLIPID DE NOVO BIOSYNTHESIS
4.13.3.2 GLYCOSPHINGOLIPID METABOLISM
4.13.4 KETONE BODY METABOLISM
4.13.4.1 UTILIZATION OF KETONE BODIES
4.13.4.2 SYNTHESIS OF KETONE BODIES
4.13.5 PLASMALOGEN BIOSYNTHESIS
4.13.6 WAX BIOSYNTHESIS
4.13.7 METABOLISM OF STEROIDS
4.13.7.1 REGULATION OF CHOLESTEROL BIOSYNTHESIS BY SREBP (SREBF)
4.13.7.1.1 ACTIVATION OF GENE EXPRESSION BY SREBF (SREBP)
4.13.7.2 CHOLESTEROL BIOSYNTHESIS
4.13.7.2.1 CHOLESTEROL BIOSYNTHESIS VIA DESMOSTEROL
4.13.7.2.2 CHOLESTEROL BIOSYNTHESIS VIA LATHOSTEROL
4.13.7.3 BILE ACID AND BILE SALT METABOLISM
4.13.7.3.1 RECYCLING OF BILE ACIDS AND SALTS
4.13.7.3.2 SYNTHESIS OF BILE ACIDS AND BILE SALTS
4.13.7.3.2.1 SYNTHESIS OF BILE ACIDS AND BILE SALTS VIA 7ALPHA-HYDROXYCHOLESTEROL
4.13.7.3.2.2 SYNTHESIS OF BILE ACIDS AND BILE SALTS VIA 24-HYDROXYCHOLESTEROL
4.13.7.3.2.3 SYNTHESIS OF BILE ACIDS AND BILE SALTS VIA 27-HYDROXYCHOLESTEROL
4.13.7.4 METABOLISM OF STEROID HORMONES
4.13.7.4.1 ANDROGEN BIOSYNTHESIS
4.13.7.4.2 ESTROGEN BIOSYNTHESIS
4.13.7.4.3 MINERALOCORTICOID BIOSYNTHESIS
4.13.7.4.4 GLUCOCORTICOID BIOSYNTHESIS
4.13.7.4.5 PREGNENOLONE BIOSYNTHESIS
4.13.7.5 VITAMIN D (CALCIFEROL) METABOLISM
4.13.8 LIPID PARTICLE ORGANIZATION
4.13.9 FATTY ACID METABOLISM
4.13.9.1 IMPORT OF PALMITOYL-COA INTO THE MITOCHONDRIAL MATRIX
4.13.9.2 ALPHA-LINOLENIC (OMEGA3) AND LINOLEIC (OMEGA6) ACID METABOLISM
4.13.9.2.1 LINOLEIC ACID (LA) METABOLISM
4.13.9.2.2 ALPHA-LINOLENIC ACID (ALA) METABOLISM
4.13.9.3 ARACHIDONIC ACID METABOLISM
4.13.9.3.1 SYNTHESIS OF EPOXY (EET) AND DIHYDROXYEICOSATRIENOIC ACIDS (DHET)
4.13.9.3.2 SYNTHESIS OF 5-EICOSATETRAENOIC ACIDS
4.13.9.3.3 SYNTHESIS OF LEUKOTRIENES (LT) AND EOXINS (EX)
4.13.9.3.4 SYNTHESIS OF HEPOXILINS (HX) AND TRIOXILINS (TRX)
4.13.9.3.5 SYNTHESIS OF 12-EICOSATETRAENOIC ACID DERIVATIVES
4.13.9.3.6 SYNTHESIS OF 15-EICOSATETRAENOIC ACID DERIVATIVES
4.13.9.3.7 SYNTHESIS OF (16-20)-HYDROXYEICOSATETRAENOIC ACIDS (HETE)
4.13.9.3.8 SYNTHESIS OF PROSTAGLANDINS (PG) AND THROMBOXANES (TX)
4.13.9.4 PEROXISOMAL LIPID METABOLISM
4.13.9.4.1 ALPHA-OXIDATION OF PHYTANATE
4.13.9.4.2 BETA-OXIDATION OF PRISTANOYL-COA
4.13.9.4.3 BETA-OXIDATION OF VERY LONG CHAIN FATTY ACIDS
4.13.9.5 FATTY ACYL-COA BIOSYNTHESIS
4.13.9.5.1 SYNTHESIS OF VERY LONG-CHAIN FATTY ACYL-COAS
4.13.9.6 MITOCHONDRIAL FATTY ACID BETA-OXIDATION
4.13.9.6.1 PROPIONYL-COA CATABOLISM
4.13.9.6.2 MITOCHONDRIAL FATTY ACID BETA-OXIDATION OF SATURATED FATTY ACIDS
4.13.9.6.2.1 BETA OXIDATION OF MYRISTOYL-COA TO LAUROYL-COA
4.13.9.6.2.2 BETA OXIDATION OF PALMITOYL-COA TO MYRISTOYL-COA
4.13.9.6.2.3 BETA OXIDATION OF LAUROYL-COA TO DECANOYL-COA-COA
4.13.9.6.2.4 BETA OXIDATION OF DECANOYL-COA TO OCTANOYL-COA-COA
4.13.9.6.2.5 BETA OXIDATION OF OCTANOYL-COA TO HEXANOYL-COA
4.13.9.6.2.6 BETA OXIDATION OF HEXANOYL-COA TO BUTANOYL-COA
4.13.9.6.2.7 BETA OXIDATION OF BUTANOYL-COA TO ACETYL-COA
4.13.9.6.3 MITOCHONDRIAL FATTY ACID BETA-OXIDATION OF UNSATURATED FATTY ACIDS
4.13.10 TRIGLYCERIDE METABOLISM
4.13.10.1 TRIGLYCERIDE CATABOLISM
4.13.10.2 TRIGLYCERIDE BIOSYNTHESIS
4.13.11 BIOSYNTHESIS OF SPECIALIZED PRORESOLVING MEDIATORS (SPMS)
4.13.11.1 SYNTHESIS OF LIPOXINS (LX)
4.13.11.2 BIOSYNTHESIS OF DHA-DERIVED SPMS
4.13.11.2.1 BIOSYNTHESIS OF D-SERIES RESOLVINS
4.13.11.2.2 BIOSYNTHESIS OF PROTECTINS
4.13.11.2.3 BIOSYNTHESIS OF MARESINS
4.13.11.2.3.1 BIOSYNTHESIS OF MARESIN-LIKE SPMS
4.13.11.2.4 BIOSYNTHESIS OF ASPIRIN-TRIGGERED D-SERIES RESOLVINS
4.13.11.2.5 BIOSYNTHESIS OF DHA-DERIVED SULFIDO CONJUGATES
4.13.11.2.5.1 BIOSYNTHESIS OF MARESIN CONJUGATES IN TISSUE REGENERATION (MCTR)
4.13.11.2.5.2 BIOSYNTHESIS OF PROTECTIN AND RESOLVIN CONJUGATES IN TISSUE REGENERATION (PCTR AND RCTR)
4.13.11.3 BIOSYNTHESIS OF EPA-DERIVED SPMS
4.13.11.3.1 BIOSYNTHESIS OF E-SERIES 18(S)-RESOLVINS
4.13.11.3.2 BIOSYNTHESIS OF E-SERIES 18(R)-RESOLVINS
4.13.11.4 BIOSYNTHESIS OF DPA-DERIVED SPMS
4.13.11.4.1 BIOSYNTHESIS OF DPAN-3 SPMS
4.13.11.4.1.1 BIOSYNTHESIS OF DPAN-3-DERIVED PROTECTINS AND RESOLVINS
4.13.11.4.1.2 BIOSYNTHESIS OF DPAN-3-DERIVED MARESINS
4.13.11.4.1.3 BIOSYNTHESIS OF DPAN-3-DERIVED 13-SERIES RESOLVINS
4.13.11.4.2 BIOSYNTHESIS OF DPAN-6 SPMS
4.13.11.5 BIOSYNTHESIS OF ELECTROPHILIC Î©-3 PUFA OXO-DERIVATIVES
4.14 METABOLISM OF AMINO ACIDS AND DERIVATIVES
4.14.1 SULFUR AMINO ACID METABOLISM
4.14.1.1 METHIONINE SALVAGE PATHWAY
4.14.1.2 DEGRADATION OF CYSTEINE AND HOMOCYSTEINE
4.14.1.2.1 SULFIDE OXIDATION TO SULFATE
4.14.1.3 CYSTEINE FORMATION FROM HOMOCYSTEINE
4.14.2 AMINE-DERIVED HORMONES
4.14.2.1 CATECHOLAMINE BIOSYNTHESIS
4.14.2.2 SEROTONIN AND MELATONIN BIOSYNTHESIS
4.14.2.3 THYROXINE BIOSYNTHESIS
4.14.2.3.1 REGULATION OF THYROID HORMONE ACTIVITY
4.14.3 SELENOAMINO ACID METABOLISM
4.14.3.2 "METABOLISM OF INGESTED SEMET, SEC, MESEC INTO H2SE"
4.14.3.3 SEMET INCORPORATION INTO PROTEINS
4.14.3.4 METABOLISM OF INGESTED H2SEO4 AND H2SEO3 INTO H2SE
4.14.3.5 METHYLATION OF MESEH FOR EXCRETION
4.14.3.6 SELENOCYSTEINE SYNTHESIS
4.14.3.7 METABOLISM OF INGESTED MESEO2H INTO MESEH
4.14.4 METABOLISM OF POLYAMINES
4.14.4.1 METHIONINE SALVAGE PATHWAY
4.14.4.2 REGULATION OF ORNITHINE DECARBOXYLASE (ODC)
4.14.4.3 AGMATINE BIOSYNTHESIS
4.14.4.4 INTERCONVERSION OF POLYAMINES
4.14.4.5 UREA CYCLE
4.14.4.6 CREATINE METABOLISM
4.14.5 GLYOXYLATE METABOLISM AND GLYCINE DEGRADATION
4.14.5.1 GLYCINE DEGRADATION
4.14.6 MELANIN BIOSYNTHESIS
4.14.7 "HISTIDINE, LYSINE, PHENYLALANINE, TYROSINE, PROLINE AND TRYPTOPHAN CATABOLISM"
4.14.7.1 PROLINE CATABOLISM
4.14.7.2 HISTIDINE CATABOLISM
4.14.7.3 LYSINE CATABOLISM
4.14.7.4 PHENYLALANINE AND TYROSINE CATABOLISM
4.14.7.5 TRYPTOPHAN CATABOLISM
4.14.8 CHOLINE CATABOLISM
4.14.9 AMINO ACID SYNTHESIS AND INTERCONVERSION (TRANSAMINATION)
4.14.9.1 SERINE BIOSYNTHESIS
4.14.10 BRANCHED-CHAIN AMINO ACID CATABOLISM
4.14.10.1 CARNITINE SYNTHESIS
4.14.11 THREONINE CATABOLISM
4.15 METABOLISM OF CARBOHYDRATES
4.15.1 GLYCOSAMINOGLYCAN METABOLISM
4.15.1.1 KERATAN SULFATE/KERATIN METABOLISM
4.15.1.1.1 KERATAN SULFATE BIOSYNTHESIS
4.15.1.1.2 KERATAN SULFATE DEGRADATION
4.15.1.2 HEPARAN SULFATE/HEPARIN (HS-GAG) METABOLISM
4.15.1.2.1 A TETRASACCHARIDE LINKER SEQUENCE IS REQUIRED FOR GAG SYNTHESIS
4.15.1.2.2 HS-GAG BIOSYNTHESIS
4.15.1.2.3 HS-GAG DEGRADATION
4.15.1.3 TRANSPORT AND SYNTHESIS OF PAPS
4.15.1.4 CHONDROITIN SULFATE/DERMATAN SULFATE METABOLISM
4.15.1.4.1 A TETRASACCHARIDE LINKER SEQUENCE IS REQUIRED FOR GAG SYNTHESIS
4.15.1.4.2 CHONDROITIN SULFATE BIOSYNTHESIS
4.15.1.4.3 DERMATAN SULFATE BIOSYNTHESIS
4.15.1.4.4 CS/DS DEGRADATION
4.15.1.5 HYALURONAN METABOLISM
4.15.1.5.1 HYALURONAN BIOSYNTHESIS AND EXPORT
4.15.1.5.2 HYALURONAN UPTAKE AND DEGRADATION
4.15.2 FRUCTOSE METABOLISM
4.15.2.1 FRUCTOSE BIOSYNTHESIS
4.15.2.2 FRUCTOSE CATABOLISM
4.15.3 LACTOSE SYNTHESIS
4.15.4 FORMATION OF XYLULOSE-5-PHOSPHATE
4.15.5 GLUCOSE METABOLISM
4.15.5.1 GLYCOLYSIS
4.15.5.1.1 REGULATION OF GLUCOKINASE BY GLUCOKINASE REGULATORY PROTEIN
4.15.5.2 GLUCONEOGENESIS
4.15.6 GALACTOSE CATABOLISM
4.15.7 PENTOSE PHOSPHATE PATHWAY
4.15.7.1 5-PHOSPHORIBOSE 1-DIPHOSPHATE BIOSYNTHESIS
4.15.8 LYSOSOMAL OLIGOSACCHARIDE CATABOLISM
4.15.9 GLYCOGEN METABOLISM
4.15.9.1 GLYCOGEN SYNTHESIS
4.15.9.2 GLYCOGEN BREAKDOWN (GLYCOGENOLYSIS)
4.16 PYROPHOSPHATE HYDROLYSIS
5 REPRODUCTION
5.1 FERTILIZATION
5.1.1 SPERM MOTILITY AND TAXES
5.1.2 INTERACTION WITH THE ZONA PELLUCIDA
5.1.3 ACROSOME REACTION
5.1.4 SPERM:OOCYTE MEMBRANE BINDING
5.1.5 INTERACTION WITH CUMULUS CELLS
5.2 MEIOSIS
5.2.1 MEIOTIC SYNAPSIS
5.2.2 MEIOTIC RECOMBINATION
6 EXTRACELLULAR MATRIX ORGANIZATION
6.1 DEGRADATION OF THE EXTRACELLULAR MATRIX
6.1.1 COLLAGEN DEGRADATION
6.1.2 ACTIVATION OF MATRIX METALLOPROTEINASES
6.2 COLLAGEN FORMATION
6.2.1 COLLAGEN BIOSYNTHESIS AND MODIFYING ENZYMES
6.2.1.1 COLLAGEN CHAIN TRIMERIZATION
6.2.2 ASSEMBLY OF COLLAGEN FIBRILS AND OTHER MULTIMERIC STRUCTURES
6.2.2.1 ANCHORING FIBRIL FORMATION
6.2.2.2 CROSSLINKING OF COLLAGEN FIBRILS
6.3 ELASTIC FIBRE FORMATION
6.3.1 MOLECULES ASSOCIATED WITH ELASTIC FIBRES
6.4 FIBRONECTIN MATRIX FORMATION
6.5 INTEGRIN CELL SURFACE INTERACTIONS
6.6 LAMININ INTERACTIONS
6.7 NON-INTEGRIN MEMBRANE-ECM INTERACTIONS
6.7.1 SYNDECAN INTERACTIONS
6.8 ECM PROTEOGLYCANS
6.9 INVADOPODIA FORMATION
7 CELL-CELL COMMUNICATION
7.1 NEPHRIN FAMILY INTERACTIONS
7.2 SIGNAL REGULATORY PROTEIN FAMILY INTERACTIONS
7.3 CELL JUNCTION ORGANIZATION
7.3.1 CELL-CELL JUNCTION ORGANIZATION
7.3.1.1 SDK INTERACTIONS
7.3.1.2 ADHERENS JUNCTIONS INTERACTIONS
7.3.1.2.1 NECTIN/NECL  TRANS HETERODIMERIZATION
7.3.1.3 TIGHT JUNCTION INTERACTIONS
7.3.2 TYPE I HEMIDESMOSOME ASSEMBLY
7.3.3 CELL-EXTRACELLULAR MATRIX INTERACTIONS
7.3.3.1 LOCALIZATION OF THE PINCH-ILK-PARVIN COMPLEX TO FOCAL ADHESIONS
7.3.3.2 REGULATION OF CYTOSKELETAL REMODELING AND CELL SPREADING BY IPP COMPLEX COMPONENTS
8 SIGNAL TRANSDUCTION
8.1 SIGNALING BY NOTCH
8.1.1 PRE-NOTCH EXPRESSION AND PROCESSING
8.1.1.1 PRE-NOTCH PROCESSING IN THE ENDOPLASMIC RETICULUM
8.1.1.2 PRE-NOTCH TRANSCRIPTION AND TRANSLATION
8.1.1.3 PRE-NOTCH PROCESSING IN GOLGI
8.1.2 SIGNALING BY NOTCH1
8.1.2.1 NOTCH1 INTRACELLULAR DOMAIN REGULATES TRANSCRIPTION
8.1.2.2 ACTIVATED NOTCH1 TRANSMITS SIGNAL TO THE NUCLEUS
8.1.3 SIGNALING BY NOTCH2
8.1.3.1 NOTCH2 INTRACELLULAR DOMAIN REGULATES TRANSCRIPTION
8.1.3.2 NOTCH2 ACTIVATION AND TRANSMISSION OF SIGNAL TO THE NUCLEUS
8.1.4 SIGNALING BY NOTCH3
8.1.4.1 NOTCH3 ACTIVATION AND TRANSMISSION OF SIGNAL TO THE NUCLEUS
8.1.4.1.1 NONCANONICAL ACTIVATION OF NOTCH3
8.1.4.2 NOTCH3 INTRACELLULAR DOMAIN REGULATES TRANSCRIPTION
8.1.5 SIGNALING BY NOTCH4
8.1.5.1 NOTCH4 INTRACELLULAR DOMAIN REGULATES TRANSCRIPTION
8.1.5.2 NOTCH4 ACTIVATION AND TRANSMISSION OF SIGNAL TO THE NUCLEUS
8.1.5.3 NEGATIVE REGULATION OF NOTCH4 SIGNALING
8.2 MTOR SIGNALLING
8.2.1 INHIBITION OF TSC COMPLEX FORMATION BY PKB
8.2.2 MTORC1-MEDIATED SIGNALLING
8.2.3 ENERGY DEPENDENT REGULATION OF MTOR BY LKB1-AMPK
8.3 SIGNALING BY RHO GTPASES
8.3.1 RHO GTPASE CYCLE
8.3.2 RHO GTPASE EFFECTORS
8.3.2.1 RHO GTPASES ACTIVATE PKNS
8.3.2.1.1 ACTIVATED PKN1 STIMULATES TRANSCRIPTION OF AR (ANDROGEN RECEPTOR) REGULATED GENES KLK2 AND KLK3
8.3.2.2 RHO GTPASES ACTIVATE CIT
8.3.2.3 RHO GTPASES ACTIVATE KTN1
8.3.2.4 RHO GTPASES ACTIVATE IQGAPS
8.3.2.5 RHO GTPASES REGULATE CFTR TRAFFICKING
8.3.2.6 RHO GTPASES ACTIVATE ROCKS
8.3.2.7 RHO GTPASES ACTIVATE PAKS
8.3.2.8 RHO GTPASES ACTIVATE WASPS AND WAVES
8.3.2.9 RHO GTPASES ACTIVATE FORMINS
8.3.2.10 RHO GTPASES ACTIVATE RHOTEKIN AND RHOPHILINS
8.3.2.11 RHO GTPASES ACTIVATE NADPH OXIDASES
8.4 SIGNALING BY WNT
8.4.1 DEGRADATION OF BETA-CATENIN BY THE DESTRUCTION COMPLEX
8.4.1.1 BETA-CATENIN PHOSPHORYLATION CASCADE
8.4.1.2 REPRESSION OF WNT TARGET GENES
8.4.2 TCF DEPENDENT SIGNALING IN RESPONSE TO WNT
8.4.2.1 WNT MEDIATED ACTIVATION OF DVL
8.4.2.2 FORMATION OF THE BETA-CATENIN:TCF TRANSACTIVATING COMPLEX
8.4.2.2.1 BINDING OF TCF/LEF:CTNNB1 TO TARGET GENE PROMOTERS
8.4.2.3 DEACTIVATION OF THE BETA-CATENIN TRANSACTIVATING COMPLEX
8.4.2.4 NEGATIVE REGULATION OF TCF-DEPENDENT SIGNALING BY WNT LIGAND ANTAGONISTS
8.4.2.5 DEGRADATION OF AXIN
8.4.2.6 DEGRADATION OF DVL
8.4.2.7 DISASSEMBLY OF THE DESTRUCTION COMPLEX AND RECRUITMENT OF AXIN TO THE MEMBRANE
8.4.2.8 REGULATION OF FZD BY UBIQUITINATION
8.4.2.9 NEGATIVE REGULATION OF TCF-DEPENDENT SIGNALING BY DVL-INTERACTING PROTEINS
8.4.3 WNT LIGAND BIOGENESIS AND TRAFFICKING
8.4.4 BETA-CATENIN INDEPENDENT WNT SIGNALING
8.4.4.1 CA2+ PATHWAY
8.4.4.2 PCP/CE PATHWAY
8.4.4.2.1 ASYMMETRIC LOCALIZATION OF PCP PROTEINS
8.4.4.2.2 WNT5A-DEPENDENT INTERNALIZATION OF FZD4
8.4.4.2.3 "WNT5A-DEPENDENT INTERNALIZATION OF FZD2, FZD5 AND ROR2"
8.5 SIGNALING BY HIPPO
8.6 SIGNALING BY LEPTIN
8.7 SIGNALING BY GPCR
8.7.1 GPCR DOWNSTREAM SIGNALLING
8.7.1.1 G-PROTEIN BETA:GAMMA SIGNALLING
8.7.1.1.1 G BETA:GAMMA SIGNALLING THROUGH PI3KGAMMA
8.7.1.1.2 G BETA:GAMMA SIGNALLING THROUGH PLC BETA
8.7.1.1.3 G BETA:GAMMA SIGNALLING THROUGH BTK
8.7.1.1.4 G BETA:GAMMA SIGNALLING THROUGH CDC42
8.7.1.2 G ALPHA (Q) SIGNALLING EVENTS
8.7.1.2.1 EFFECTS OF PIP2 HYDROLYSIS
8.7.1.2.1.1 ARACHIDONATE PRODUCTION FROM DAG
8.7.1.2.2 GASTRIN-CREB SIGNALLING PATHWAY VIA PKC AND MAPK
8.7.1.2.2.1 EGFR TRANSACTIVATION BY GASTRIN
8.7.1.3 G ALPHA (12/13) SIGNALLING EVENTS
8.7.1.4 G ALPHA (S) SIGNALLING EVENTS
8.7.1.4.1 OLFACTORY SIGNALING PATHWAY
8.7.1.5 G ALPHA (I) SIGNALLING EVENTS
8.7.1.5.1 OPIOID SIGNALLING
8.7.1.5.1.1 G-PROTEIN MEDIATED EVENTS
8.7.1.5.1.1.1 PLC BETA MEDIATED EVENTS
8.7.1.5.1.1.1.1 CA-DEPENDENT EVENTS
8.7.1.5.1.1.1.1.1 PHOSPHO-PLA2 PATHWAY
8.7.1.5.1.1.1.1.2 CAM PATHWAY
8.7.1.5.1.1.1.1.2.1 CALMODULIN INDUCED EVENTS
8.7.1.5.1.1.1.1.2.1.1 PKA-MEDIATED PHOSPHORYLATION OF CREB
8.7.1.5.1.1.1.1.2.1.2 CAMK IV-MEDIATED PHOSPHORYLATION OF CREB
8.7.1.5.1.1.1.1.2.1.3 CAM-PDE 1 ACTIVATION
8.7.1.5.1.1.2 ADENYLATE CYCLASE ACTIVATING PATHWAY
8.7.1.5.1.1.3 ADENYLATE CYCLASE INHIBITORY PATHWAY
8.7.1.5.1.2 DARPP-32 EVENTS
8.7.1.5.1.3 G-PROTEIN ACTIVATION
8.7.1.5.2 VISUAL PHOTOTRANSDUCTION
8.7.1.5.2.1 THE RETINOID CYCLE IN CONES (DAYLIGHT VISION)
8.7.1.5.2.2 THE CANONICAL RETINOID CYCLE IN RODS (TWILIGHT VISION)
8.7.1.5.2.2.1 "BIOSYNTHESIS OF A2E, IMPLICATED IN RETINAL DEGRADATION"
8.7.1.5.2.3 THE PHOTOTRANSDUCTION CASCADE
8.7.1.5.2.3.1 ACTIVATION OF THE PHOTOTRANSDUCTION CASCADE
8.7.1.5.2.3.2 "INACTIVATION, RECOVERY AND REGULATION OF THE PHOTOTRANSDUCTION CASCADE"
8.7.1.5.2.4 RETINOID METABOLISM AND TRANSPORT
8.7.1.6 G ALPHA (Z) SIGNALLING EVENTS
8.7.2 GPCR LIGAND BINDING
8.7.2.1 CLASS A/1 (RHODOPSIN-LIKE RECEPTORS)
8.7.2.1.1 HYDROXYCARBOXYLIC ACID-BINDING RECEPTORS
8.7.2.1.2 PEPTIDE LIGAND-BINDING RECEPTORS
8.7.2.1.2.1 TACHYKININ RECEPTORS BIND TACHYKININS
8.7.2.1.2.2 CHEMOKINE RECEPTORS BIND CHEMOKINES
8.7.2.1.2.3 VASOPRESSIN-LIKE RECEPTORS
8.7.2.1.2.4 OREXIN AND NEUROPEPTIDES FF AND QRFP BIND TO THEIR RESPECTIVE RECEPTORS
8.7.2.1.2.5 FORMYL PEPTIDE RECEPTORS BIND FORMYL PEPTIDES AND MANY OTHER LIGANDS
8.7.2.1.2.6 RELAXIN RECEPTORS
8.7.2.1.3 AMINE LIGAND-BINDING RECEPTORS
8.7.2.1.3.1 MUSCARINIC ACETYLCHOLINE RECEPTORS
8.7.2.1.3.2 HISTAMINE RECEPTORS
8.7.2.1.3.3 DOPAMINE RECEPTORS
8.7.2.1.3.4 SEROTONIN RECEPTORS
8.7.2.1.3.5 ADRENOCEPTORS
8.7.2.1.4 HORMONE LIGAND-BINDING RECEPTORS
8.7.2.1.5 EICOSANOID LIGAND-BINDING RECEPTORS
8.7.2.1.5.1 LEUKOTRIENE RECEPTORS
8.7.2.1.5.2 PROSTANOID LIGAND RECEPTORS
8.7.2.1.6 NUCLEOTIDE-LIKE (PURINERGIC) RECEPTORS
8.7.2.1.6.1 P2Y RECEPTORS
8.7.2.1.6.2 ADENOSINE P1 RECEPTORS
8.7.2.1.7 LYSOSPHINGOLIPID AND LPA RECEPTORS
8.7.2.1.8 OPSINS
8.7.2.1.9 FREE FATTY ACID RECEPTORS
8.7.2.2 CLASS B/2 (SECRETIN FAMILY RECEPTORS)
8.7.2.2.1 CALCITONIN-LIKE LIGAND RECEPTORS
8.7.2.2.2 GLUCAGON-TYPE LIGAND RECEPTORS
8.7.2.3 CLASS C/3 (METABOTROPIC GLUTAMATE/PHEROMONE RECEPTORS)
8.8 SIGNALING BY HEDGEHOG
8.8.1 HEDGEHOG LIGAND BIOGENESIS
8.8.1.1 RELEASE OF HH-NP FROM THE SECRETING CELL
8.8.2 HEDGEHOG 'OFF' STATE
8.8.2.1 DEGRADATION OF GLI1 BY THE PROTEASOME
8.8.2.2 DEGRADATION OF GLI2 BY THE PROTEASOME
8.8.2.3 GLI3 IS PROCESSED TO GLI3R BY THE PROTEASOME
8.8.3 HEDGEHOG 'ON' STATE
8.8.3.1 LIGAND-RECEPTOR INTERACTIONS
8.8.3.2 ACTIVATION OF SMO
8.8.3.3 GLI PROTEINS BIND PROMOTERS OF HH RESPONSIVE GENES TO PROMOTE TRANSCRIPTION
8.9 MAPK FAMILY SIGNALING CASCADES
8.9.1 MAPK1/MAPK3 SIGNALING
8.9.1.1 RAF-INDEPENDENT MAPK1/3 ACTIVATION
8.9.1.1.1 MAPK3 (ERK1) ACTIVATION
8.9.1.1.2 MAPK1 (ERK2) ACTIVATION
8.9.1.2 RAF/MAP KINASE CASCADE
8.9.1.2.1 REGULATION OF RAS BY GAPS
8.9.1.2.2 RAF ACTIVATION
8.9.1.2.3 MAP2K AND MAPK ACTIVATION
8.9.1.2.4 NEGATIVE REGULATION OF MAPK PATHWAY
8.9.1.2.4.1 NEGATIVE FEEDBACK REGULATION OF MAPK PATHWAY
8.9.2 MAPK6/MAPK4 SIGNALING
8.1 DEATH RECEPTOR SIGNALLING
8.10.1 P75 NTR RECEPTOR-MEDIATED SIGNALLING
8.10.1.1 P75NTR SIGNALS VIA NF-KB
8.10.1.1.1 P75NTR RECRUITS SIGNALLING COMPLEXES
8.10.1.1.2 NF-KB IS ACTIVATED AND SIGNALS SURVIVAL
8.10.1.2 P75NTR NEGATIVELY REGULATES CELL CYCLE VIA SC1
8.10.1.3 CERAMIDE SIGNALLING
8.10.1.4 REGULATED PROTEOLYSIS OF P75NTR
8.10.1.5 P75NTR REGULATES AXONOGENESIS
8.10.1.5.1 AXONAL GROWTH INHIBITION (RHOA ACTIVATION)
8.10.1.5.2 AXONAL GROWTH STIMULATION
8.10.1.6 "CELL DEATH SIGNALLING VIA NRAGE, NRIF AND NADE"
8.10.1.6.1 NRAGE SIGNALS DEATH THROUGH JNK
8.10.1.6.2 NADE MODULATES DEATH SIGNALLING
8.10.1.6.3 NRIF SIGNALS CELL DEATH FROM THE NUCLEUS
8.10.1.7 NFG AND PRONGF BINDS TO P75NTR
8.10.2 FASL/ CD95L SIGNALING
8.10.3 TRAIL  SIGNALING
8.10.4 TNF SIGNALING
8.10.4.1 TNFR1-INDUCED PROAPOPTOTIC SIGNALING
8.10.4.2 REGULATION OF TNFR1 SIGNALING
8.10.4.3 TNFR1-INDUCED NFKAPPAB SIGNALING PATHWAY
8.10.4.4 TNFR1-MEDIATED CERAMIDE PRODUCTION
8.11 SIGNALING BY ERYTHROPOIETIN
8.11.1 ERYTHROPOIETIN ACTIVATES PHOSPHOINOSITIDE-3-KINASE (PI3K)
8.11.2 ERYTHROPOIETIN ACTIVATES PHOSPHOLIPASE C GAMMA (PLCG)
8.11.3 ERYTHROPOIETIN ACTIVATES STAT5
8.11.4 ERYTHROPOIETIN ACTIVATES RAS
8.12 INTEGRIN SIGNALING
8.12.1 INTEGRIN ALPHAIIB BETA3 SIGNALING
8.12.1.1 GRB2:SOS PROVIDES LINKAGE TO MAPK SIGNALING FOR INTEGRINS
8.12.1.2 P130CAS LINKAGE TO MAPK SIGNALING FOR INTEGRINS
8.13 INTRACELLULAR SIGNALING BY SECOND MESSENGERS
8.13.1 PIP3 ACTIVATES AKT SIGNALING
8.13.1.1 AKT PHOSPHORYLATES TARGETS IN THE CYTOSOL
8.13.1.2 AKT PHOSPHORYLATES TARGETS IN THE NUCLEUS
8.13.1.3 NEGATIVE REGULATION OF THE PI3K/AKT NETWORK
8.13.1.3.1 "PI5P, PP2A AND IER3 REGULATE PI3K/AKT SIGNALING"
8.13.1.4 PTEN REGULATION
8.13.1.4.1 REGULATION OF PTEN MRNA TRANSLATION
8.13.1.4.1.1 COMPETING ENDOGENOUS RNAS (CERNAS) REGULATE PTEN TRANSLATION
8.13.1.4.2 REGULATION OF PTEN GENE TRANSCRIPTION
8.13.1.4.3 REGULATION OF PTEN LOCALIZATION
8.13.1.4.4 REGULATION OF PTEN STABILITY AND ACTIVITY
8.13.2 DAG AND IP3 SIGNALING
8.13.2.1 CAM PATHWAY
8.13.2.1.1 CALMODULIN INDUCED EVENTS
8.13.2.1.1.1 PKA-MEDIATED PHOSPHORYLATION OF CREB
8.13.2.1.1.1.1 PKA ACTIVATION
8.13.2.1.1.2 CAMK IV-MEDIATED PHOSPHORYLATION OF CREB
8.13.2.1.1.3 CAM-PDE 1 ACTIVATION
8.14 SIGNALING BY NON-RECEPTOR TYROSINE KINASES
8.14.1 SIGNALING BY PTK6
8.14.1.1 ERBB2 ACTIVATES PTK6 SIGNALING
8.14.1.2 PTK6 REGULATES PROTEINS INVOLVED IN RNA PROCESSING
8.14.1.3 PTK6 REGULATES RTKS AND THEIR EFFECTORS AKT1 AND DOK1
8.14.1.4 PTK6 REGULATES CELL CYCLE
8.14.1.5 "PTK6 REGULATES RHO GTPASES, RAS GTPASE AND MAP KINASES"
8.14.1.6 PTK6 DOWN-REGULATION
8.14.1.7 PTK6 EXPRESSION
8.14.1.8 PTK6 ACTIVATES STAT3
8.14.1.9 PTK6 PROMOTES HIF1A STABILIZATION
8.15 SIGNALING BY NUCLEAR RECEPTORS
8.15.1 SIGNALING BY RETINOIC ACID
8.15.1.1 RA BIOSYNTHESIS PATHWAY
8.15.2 ESR-MEDIATED SIGNALING
8.15.2.1 ESTROGEN-DEPENDENT GENE EXPRESSION
8.16 SIGNALING BY RECEPTOR TYROSINE KINASES
8.16.1 SIGNALING BY ERBB2
8.16.1.1 SHC1 EVENTS IN ERBB2 SIGNALING
8.16.1.2 PLCG1 EVENTS IN ERBB2 SIGNALING
8.16.1.3 GRB7 EVENTS IN ERBB2 SIGNALING
8.16.1.4 GRB2 EVENTS IN ERBB2 SIGNALING
8.16.1.5 PI3K EVENTS IN ERBB2 SIGNALING
8.16.1.6 ERBB2 REGULATES CELL MOTILITY
8.16.1.7 ERBB2 ACTIVATES PTK6 SIGNALING
8.16.1.8 DOWNREGULATION OF ERBB2 SIGNALING
8.16.1.8.1 DOWNREGULATION OF ERBB2:ERBB3 SIGNALING
8.16.2 SIGNALING BY ERBB4
8.16.2.1 PI3K EVENTS IN ERBB4 SIGNALING
8.16.2.2 SHC1 EVENTS IN ERBB4 SIGNALING
8.16.2.3 NUCLEAR SIGNALING BY ERBB4
8.16.2.4 DOWNREGULATION OF ERBB4 SIGNALING
8.16.3 SIGNALING BY SCF-KIT
8.16.3.1 REGULATION OF KIT SIGNALING
8.16.4 SIGNALING BY NTRKS
8.16.4.1 SIGNALING BY NTRK1 (TRKA)
8.16.4.1.1 PLC-GAMMA1 SIGNALLING
8.16.4.1.2 RETROGRADE NEUROTROPHIN SIGNALLING
8.16.4.1.3 ACTIVATION OF TRKA RECEPTORS
8.16.4.1.3.1 NGF-INDEPENDANT TRKA ACTIVATION
8.16.4.1.3.2 TRKA ACTIVATION BY NGF
8.16.4.1.4 SIGNALLING TO ERKS
8.16.4.1.4.1 SIGNALLING TO RAS
8.16.4.1.4.1.1 P38MAPK EVENTS
8.16.4.1.4.2 PROLONGED ERK ACTIVATION EVENTS
8.16.4.1.4.2.1 FRS2-MEDIATED ACTIVATION
8.16.4.1.4.2.2 ARMS-MEDIATED ACTIVATION
8.16.4.1.4.3 SIGNALLING TO P38 VIA RIT AND RIN
8.16.4.1.5 PI3K/AKT ACTIVATION
8.16.4.1.6 NUCLEAR EVENTS (KINASE AND TRANSCRIPTION FACTOR ACTIVATION)
8.16.4.1.6.1 ERK/MAPK TARGETS
8.16.4.1.6.1.1 ERKS ARE INACTIVATED
8.16.4.1.6.2 CREB PHOSPHORYLATION
8.16.4.1.7 SIGNALLING TO STAT3
8.16.4.1.8 SIGNALLING TO ERK5
8.16.4.2 SIGNALING BY NTRK2 (TRKB)
8.16.4.2.1 BDNF ACTIVATES NTRK2 (TRKB) SIGNALING
8.16.4.2.2 NTF3 ACTIVATES NTRK2 (TRKB) SIGNALING
8.16.4.2.3 NTF4 ACTIVATES NTRK2 (TRKB) SIGNALING
8.16.4.2.4 ACTIVATED NTRK2 SIGNALS THROUGH RAS
8.16.4.2.5 ACTIVATED NTRK2 SIGNALS THROUGH PLCG1
8.16.4.2.6 ACTIVATED NTRK2 SIGNALS THROUGH PI3K
8.16.4.2.7 ACTIVATED NTRK2 SIGNALS THROUGH FRS2 AND FRS3
8.16.4.2.8 ACTIVATED NTRK2 SIGNALS THROUGH FYN
8.16.4.2.8.1 NTRK2 ACTIVATES RAC1
8.16.4.2.9 ACTIVATED NTRK2 SIGNALS THROUGH CDK5
8.16.4.3 SIGNALING BY NTRK3 (TRKC)
8.16.4.3.1 NTF3 ACTIVATES NTRK3 SIGNALING
8.16.4.3.2 ACTIVATED NTRK3 SIGNALS THROUGH PLCG1
8.16.4.3.3 ACTIVATED NTRK3 SIGNALS THROUGH RAS
8.16.4.3.4 ACTIVATED NTRK3 SIGNALS THROUGH PI3K
8.16.4.3.5 NTRK3 AS A DEPENDENCE RECEPTOR
8.16.4.4 EXPRESSION AND PROCESSING OF NEUROTROPHINS
8.16.4.4.1 NGF PROCESSING
8.16.5 SIGNALING BY EGFR
8.16.5.1 GRB2 EVENTS IN EGFR SIGNALING
8.16.5.2 GAB1 SIGNALOSOME
8.16.5.3 SHC1 EVENTS IN EGFR SIGNALING
8.16.5.4 EGFR DOWNREGULATION
8.16.5.5 EGFR INTERACTS WITH PHOSPHOLIPASE C-GAMMA
8.16.6 SIGNALING BY PDGF
8.16.6.1 DOWNSTREAM SIGNAL TRANSDUCTION
8.16.7 SIGNALING BY FGFR
8.16.7.1 SIGNALING BY FGFR1
8.16.7.1.1 FGFR1 LIGAND BINDING AND ACTIVATION
8.16.7.1.1.1 FGFR1B LIGAND BINDING AND ACTIVATION
8.16.7.1.1.2 FGFR1C LIGAND BINDING AND ACTIVATION
8.16.7.1.1.3 FGFR1C AND KLOTHO LIGAND BINDING AND ACTIVATION
8.16.7.1.2 DOWNSTREAM SIGNALING OF ACTIVATED FGFR1
8.16.7.1.2.1 PHOSPHOLIPASE C-MEDIATED CASCADE: FGFR1
8.16.7.1.2.2 SHC-MEDIATED CASCADE:FGFR1
8.16.7.1.2.3 PI-3K CASCADE:FGFR1
8.16.7.1.2.4 FRS-MEDIATED FGFR1 SIGNALING
8.16.7.1.3 NEGATIVE REGULATION OF FGFR1 SIGNALING
8.16.7.1.3.1 SPRY REGULATION OF FGF SIGNALING
8.16.7.1.4 FGFRL1 MODULATION OF FGFR1 SIGNALING
8.16.7.2 SIGNALING BY FGFR2
8.16.7.2.1 FGFR2 LIGAND BINDING AND ACTIVATION
8.16.7.2.1.1 FGFR2C LIGAND BINDING AND ACTIVATION
8.16.7.2.1.2 FGFR2B LIGAND BINDING AND ACTIVATION
8.16.7.2.2 DOWNSTREAM SIGNALING OF ACTIVATED FGFR2
8.16.7.2.2.1 PHOSPHOLIPASE C-MEDIATED CASCADE; FGFR2
8.16.7.2.2.2 PI-3K CASCADE:FGFR2
8.16.7.2.2.3 SHC-MEDIATED CASCADE:FGFR2
8.16.7.2.2.4 FRS-MEDIATED FGFR2 SIGNALING
8.16.7.2.3 NEGATIVE REGULATION OF FGFR2 SIGNALING
8.16.7.2.3.1 SPRY REGULATION OF FGF SIGNALING
8.16.7.2.4 FGFR2 ALTERNATIVE SPLICING
8.16.7.3 SIGNALING BY FGFR3
8.16.7.3.1 FGFR3 LIGAND BINDING AND ACTIVATION
8.16.7.3.1.1 FGFR3B LIGAND BINDING AND ACTIVATION
8.16.7.3.1.2 FGFR3C LIGAND BINDING AND ACTIVATION
8.16.7.3.2 DOWNSTREAM SIGNALING OF ACTIVATED FGFR3
8.16.7.3.2.1 PHOSPHOLIPASE C-MEDIATED CASCADE; FGFR3
8.16.7.3.2.2 SHC-MEDIATED CASCADE:FGFR3
8.16.7.3.2.3 FRS-MEDIATED FGFR3 SIGNALING
8.16.7.3.2.4 PI-3K CASCADE:FGFR3
8.16.7.3.3 NEGATIVE REGULATION OF FGFR3 SIGNALING
8.16.7.3.3.1 SPRY REGULATION OF FGF SIGNALING
8.16.7.4 SIGNALING BY FGFR4
8.16.7.4.1 FGFR4 LIGAND BINDING AND ACTIVATION
8.16.7.4.1.1 BETAKLOTHO-MEDIATED LIGAND BINDING
8.16.7.4.2 DOWNSTREAM SIGNALING OF ACTIVATED FGFR4
8.16.7.4.2.1 PHOSPHOLIPASE C-MEDIATED CASCADE; FGFR4
8.16.7.4.2.2 FRS-MEDIATED FGFR4 SIGNALING
8.16.7.4.2.3 SHC-MEDIATED CASCADE:FGFR4
8.16.7.4.2.4 PI-3K CASCADE:FGFR4
8.16.7.4.3 NEGATIVE REGULATION OF FGFR4 SIGNALING
8.16.7.4.3.1 SPRY REGULATION OF FGF SIGNALING
8.16.8 SIGNALING BY VEGF
8.16.8.1 NEUROPHILIN INTERACTIONS WITH VEGF AND VEGFR
8.16.8.2 VEGF LIGAND-RECEPTOR INTERACTIONS
8.16.8.2.1 VEGF BINDS TO VEGFR LEADING TO RECEPTOR DIMERIZATION
8.16.8.3 VEGFA-VEGFR2 PATHWAY
8.16.8.3.1 VEGFR2 MEDIATED VASCULAR PERMEABILITY
8.16.8.3.2 VEGFR2 MEDIATED CELL PROLIFERATION
8.16.9 SIGNALING BY TYPE 1 INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF1R)
8.16.9.1 IGF1R SIGNALING CASCADE
8.16.9.1.1 IRS-RELATED EVENTS TRIGGERED BY IGF1R
8.16.9.1.1.1 IRS-MEDIATED SIGNALLING
8.16.9.1.1.1.1 PI3K CASCADE
8.16.9.1.1.1.1.1 PKB-MEDIATED EVENTS
8.16.9.1.1.1.1.1.1 PDE3B SIGNALLING
8.16.9.1.1.1.1.2 ACTIVATION OF AKT2
8.16.9.1.1.1.2 SOS-MEDIATED SIGNALLING
8.16.9.1.2 SHC-RELATED EVENTS TRIGGERED BY IGF1R
8.16.10 SIGNALING BY MET
8.16.10.1 MET RECEPTOR ACTIVATION
8.16.10.2 NEGATIVE REGULATION OF MET ACTIVITY
8.16.10.3 MET ACTIVATES RAS SIGNALING
8.16.10.4 MET ACTIVATES PI3K/AKT SIGNALING
8.16.10.5 MET ACTIVATES PTPN11
8.16.10.6 MET RECEPTOR RECYCLING
8.16.10.7 MET ACTIVATES STAT3
8.16.10.8 MET PROMOTES CELL MOTILITY
8.16.10.8.1 MET ACTIVATES PTK2 SIGNALING
8.16.10.8.2 MET INTERACTS WITH TNS PROTEINS
8.16.10.8.3 MET ACTIVATES RAP1 AND RAC1
8.16.11 SIGNALING BY INSULIN RECEPTOR
8.16.11.1 INSULIN RECEPTOR SIGNALLING CASCADE
8.16.11.1.1 IRS-MEDIATED SIGNALLING
8.16.11.1.1.1 PI3K CASCADE
8.16.11.1.1.1.1 PKB-MEDIATED EVENTS
8.16.11.1.1.1.1.1 PDE3B SIGNALLING
8.16.11.1.1.1.2 ACTIVATION OF AKT2
8.16.11.1.1.2 SOS-MEDIATED SIGNALLING
8.16.11.1.2 IRS ACTIVATION
8.16.11.1.3 SIGNAL ATTENUATION
8.16.11.2 INSULIN RECEPTOR RECYCLING
8.16.12 SIGNALING BY MST1
8.17 SIGNALING BY TGF-BETA FAMILY MEMBERS
8.17.1 SIGNALING BY ACTIVIN
8.17.1.1 ANTAGONISM OF ACTIVIN BY FOLLISTATIN
8.17.2 SIGNALING BY TGF-BETA RECEPTOR COMPLEX
8.17.2.1 TGF-BETA RECEPTOR SIGNALING ACTIVATES SMADS
8.17.2.1.1 DOWNREGULATION OF TGF-BETA RECEPTOR SIGNALING
8.17.2.2 TGF-BETA RECEPTOR SIGNALING IN EMT (EPITHELIAL TO MESENCHYMAL TRANSITION)
8.17.2.3 TRANSCRIPTIONAL ACTIVITY OF SMAD2/SMAD3:SMAD4 HETEROTRIMER
8.17.2.3.1 DOWNREGULATION OF SMAD2/3:SMAD4 TRANSCRIPTIONAL ACTIVITY
8.17.2.3.2 SMAD2/SMAD3:SMAD4 HETEROTRIMER REGULATES TRANSCRIPTION
8.17.3 SIGNALING BY BMP
9 CELL CYCLE
9.1 MEIOSIS
9.1.1 MEIOTIC SYNAPSIS
9.1.2 MEIOTIC RECOMBINATION
9.2 "CELL CYCLE, MITOTIC"
9.2.1 MITOTIC G2-G2/M PHASES
9.2.1.1 G2 PHASE
9.2.1.2 G2/M TRANSITION
9.2.1.2.1 POLO-LIKE KINASE MEDIATED EVENTS
9.2.1.2.2 REGULATION OF PLK1 ACTIVITY AT G2/M TRANSITION
9.2.1.2.3 CENTROSOME MATURATION
9.2.1.2.3.1 RECRUITMENT OF MITOTIC CENTROSOME PROTEINS AND COMPLEXES
9.2.1.2.3.2 LOSS OF PROTEINS REQUIRED FOR INTERPHASE MICROTUBULE ORGANIZATION FROM THE CENTROSOME
9.2.1.2.3.2.1 LOSS OF NLP FROM MITOTIC CENTROSOMES
9.2.1.2.4 CYCLIN A/B1/B2 ASSOCIATED EVENTS DURING G2/M TRANSITION
9.2.1.2.4.1 PHOSPHORYLATION OF PROTEINS INVOLVED IN THE G2/M TRANSITION BY CYCLIN A:CDC2 COMPLEXES
9.2.1.2.5 THE ROLE OF GTSE1 IN G2/M PROGRESSION AFTER G2 CHECKPOINT
9.2.1.2.6 FBXL7 DOWN-REGULATES AURKA DURING MITOTIC ENTRY AND IN EARLY MITOSIS
9.2.1.2.7 AURKA ACTIVATION BY TPX2
9.2.1.2.8 INTERACTION BETWEEN PHLDA1 AND AURKA
9.2.2 REGULATION OF MITOTIC CELL CYCLE
9.2.2.1 APC/C-MEDIATED DEGRADATION OF CELL CYCLE PROTEINS
9.2.2.1.1 AUTODEGRADATION OF CDH1 BY CDH1:APC/C
9.2.2.1.2 APC/C:CDH1 MEDIATED DEGRADATION OF CDC20 AND OTHER APC/C:CDH1 TARGETED PROTEINS IN LATE MITOSIS/EARLY G1
9.2.2.1.3 CONVERSION FROM APC/C:CDC20 TO APC/C:CDH1 IN LATE ANAPHASE
9.2.2.1.4 REGULATION OF APC/C ACTIVATORS BETWEEN G1/S AND EARLY ANAPHASE
9.2.2.1.4.1 INHIBITION OF THE PROTEOLYTIC ACTIVITY OF APC/C REQUIRED FOR THE ONSET OF ANAPHASE BY MITOTIC SPINDLE CHECKPOINT COMPONENTS
9.2.2.1.4.1.1 INACTIVATION OF APC/C VIA DIRECT INHIBITION OF THE APC/C COMPLEX
9.2.2.1.4.2 SCF-BETA-TRCP MEDIATED DEGRADATION OF EMI1
9.2.2.1.4.3 PHOSPHORYLATION OF EMI1
9.2.2.1.5 ACTIVATION OF APC/C AND APC/C:CDC20 MEDIATED DEGRADATION OF MITOTIC PROTEINS
9.2.2.1.5.1 APC/C:CDC20 MEDIATED DEGRADATION OF MITOTIC PROTEINS
9.2.2.1.5.1.1 APC/C:CDC20 MEDIATED DEGRADATION OF CYCLIN B
9.2.2.1.5.1.2 APC/C:CDC20 MEDIATED DEGRADATION OF SECURIN
9.2.2.1.5.1.3 APC:CDC20 MEDIATED DEGRADATION OF CELL CYCLE PROTEINS PRIOR TO SATISFATION OF THE CELL CYCLE CHECKPOINT
9.2.2.1.5.1.3.1 CDC20:PHOSPHO-APC/C MEDIATED DEGRADATION OF CYCLIN A
9.2.2.1.5.1.3.2 APC-CDC20 MEDIATED DEGRADATION OF NEK2A
9.2.2.1.5.2 PHOSPHORYLATION OF THE APC/C
9.2.3 MITOTIC G1-G1/S PHASES
9.2.3.1 G0 AND EARLY G1
9.2.3.1.1 TRANSCRIPTION OF E2F TARGETS UNDER NEGATIVE CONTROL BY DREAM COMPLEX
9.2.3.1.2 TRANSCRIPTION OF E2F TARGETS UNDER NEGATIVE CONTROL BY P107 (RBL1) AND P130 (RBL2) IN COMPLEX WITH HDAC1
9.2.3.2 G1/S TRANSITION
9.2.3.2.1 E2F MEDIATED REGULATION OF DNA REPLICATION
9.2.3.2.1.1 INHIBITION OF REPLICATION INITIATION OF DAMAGED DNA BY RB1/E2F1
9.2.3.2.1.2 E2F-ENABLED INHIBITION OF PRE-REPLICATION COMPLEX FORMATION
9.2.3.2.2 ACTIVATION OF THE PRE-REPLICATIVE COMPLEX
9.2.3.2.3 CYCLIN E ASSOCIATED EVENTS DURING G1/S TRANSITION
9.2.3.2.3.1 SCF(SKP2)-MEDIATED DEGRADATION OF P27/P21
9.2.3.2.3.2 PHOSPHORYLATION OF PROTEINS INVOLVED IN G1/S TRANSITION BY ACTIVE CYCLIN E:CDK2 COMPLEXES
9.2.3.2.4 G1/S-SPECIFIC TRANSCRIPTION
9.2.3.2.4.1 ACTIVATION OF E2F1 TARGET GENES AT G1/S
9.2.3.3 G1 PHASE
9.2.3.3.1 CYCLIN D ASSOCIATED EVENTS IN G1
9.2.4 M PHASE
9.2.4.1 MITOTIC METAPHASE AND ANAPHASE
9.2.4.1.1 MITOTIC METAPHASE/ANAPHASE TRANSITION
9.2.4.1.2 MITOTIC ANAPHASE
9.2.4.1.2.1 SEPARATION OF SISTER CHROMATIDS
9.2.4.1.2.2 NUCLEAR ENVELOPE REASSEMBLY
9.2.4.1.2.2.1 INITIATION OF NUCLEAR ENVELOPE REFORMATION
9.2.4.2 MITOTIC PROPHASE
9.2.4.2.1 GOLGI CISTERNAE PERICENTRIOLAR STACK REORGANIZATION
9.2.4.2.2 CONDENSATION OF PROPHASE CHROMOSOMES
9.2.4.2.3 MASTL FACILITATES MITOTIC PROGRESSION
9.2.4.2.4 NUCLEAR ENVELOPE BREAKDOWN
9.2.4.2.4.1 "ACTIVATION OF NIMA KINASES NEK9, NEK6, NEK7"
9.2.4.2.4.2 CLEARANCE OF NUCLEAR ENVELOPE MEMBRANES FROM CHROMATIN
9.2.4.2.4.3 NUCLEAR PORE COMPLEX (NPC) DISASSEMBLY
9.2.4.2.4.4 DEPOLYMERISATION OF THE NUCLEAR LAMINA
9.2.4.3 MITOTIC PROMETAPHASE
9.2.4.3.1 RESOLUTION OF SISTER CHROMATID COHESION
9.2.4.3.2 CONDENSATION OF PROMETAPHASE CHROMOSOMES
9.2.4.3.3 RECRUITMENT OF NUMA TO MITOTIC CENTROSOMES
9.2.4.4 MITOTIC TELOPHASE/CYTOKINESIS
9.2.4.4.1 COHESIN LOADING ONTO CHROMATIN
9.2.5 S PHASE
9.2.5.1 ESTABLISHMENT OF SISTER CHROMATID COHESION
9.2.5.2 SYNTHESIS OF DNA
9.2.5.2.1 DNA REPLICATION INITIATION
9.2.5.2.2 SWITCHING OF ORIGINS TO A POST-REPLICATIVE STATE
9.2.5.2.2.1 ORC1 REMOVAL FROM CHROMATIN
9.2.5.2.2.2 CDK-MEDIATED PHOSPHORYLATION AND REMOVAL OF CDC6
9.2.5.2.3 DNA STRAND ELONGATION
9.2.5.2.3.1 UNWINDING OF DNA
9.2.5.2.3.2 LEADING STRAND SYNTHESIS
9.2.5.2.3.2.1 POLYMERASE SWITCHING
9.2.5.2.3.3 LAGGING STRAND SYNTHESIS
9.2.5.2.3.3.1 POLYMERASE SWITCHING
9.2.5.2.3.3.2 PROCESSIVE SYNTHESIS ON THE LAGGING STRAND
9.2.5.2.3.3.2.1 REMOVAL OF THE FLAP INTERMEDIATE
9.2.5.3 CYCLIN A:CDK2-ASSOCIATED EVENTS AT S PHASE ENTRY
9.2.5.3.1 SCF(SKP2)-MEDIATED DEGRADATION OF P27/P21
9.2.5.4 UBIQUITIN-DEPENDENT DEGRADATION OF CYCLIN D
9.2.5.4.1 UBIQUITIN-DEPENDENT DEGRADATION OF CYCLIN D1
9.3 CELL CYCLE CHECKPOINTS
9.3.1 G2/M CHECKPOINTS
9.3.1.1 ACTIVATION OF ATR IN RESPONSE TO REPLICATION STRESS
9.3.1.2 G2/M DNA DAMAGE CHECKPOINT
9.3.1.2.1 CHK1/CHK2(CDS1) MEDIATED INACTIVATION OF CYCLIN B:CDK1 COMPLEX
9.3.1.3 G2/M DNA REPLICATION CHECKPOINT
9.3.2 G1/S DNA DAMAGE CHECKPOINTS
9.3.2.1 P53-DEPENDENT G1/S DNA DAMAGE CHECKPOINT
9.3.2.1.1 P53-DEPENDENT G1 DNA DAMAGE RESPONSE
9.3.2.1.1.1 STABILIZATION OF P53
9.3.2.1.1.1.1 AUTODEGRADATION OF THE E3 UBIQUITIN LIGASE COP1
9.3.2.1.1.2 TRANSCRIPTIONAL ACTIVATION OF P53 RESPONSIVE GENES
9.3.2.1.1.2.1 TRANSCRIPTIONAL  ACTIVATION OF  CELL CYCLE INHIBITOR P21
9.3.2.2 P53-INDEPENDENT G1/S DNA DAMAGE CHECKPOINT
9.3.2.2.1 P53-INDEPENDENT DNA DAMAGE RESPONSE
9.3.2.2.1.1 UBIQUITIN MEDIATED DEGRADATION OF PHOSPHORYLATED CDC25A
9.3.3 MITOTIC SPINDLE CHECKPOINT
9.3.3.1 INHIBITION OF THE PROTEOLYTIC ACTIVITY OF APC/C REQUIRED FOR THE ONSET OF ANAPHASE BY MITOTIC SPINDLE CHECKPOINT COMPONENTS
9.3.3.1.1 INACTIVATION OF APC/C VIA DIRECT INHIBITION OF THE APC/C COMPLEX
9.3.3.2 AMPLIFICATION OF SIGNAL FROM THE KINETOCHORES
9.3.3.2.1 AMPLIFICATION  OF SIGNAL FROM UNATTACHED  KINETOCHORES VIA A MAD2  INHIBITORY SIGNAL
9.4 CHROMOSOME MAINTENANCE
9.4.1 TELOMERE MAINTENANCE
9.4.1.1 PACKAGING OF TELOMERE ENDS
9.4.1.2 EXTENSION OF TELOMERES
9.4.1.2.1 TELOMERE EXTENSION BY TELOMERASE
9.4.1.2.2 TELOMERE C-STRAND (LAGGING STRAND) SYNTHESIS
9.4.1.2.2.1 POLYMERASE SWITCHING ON THE C-STRAND OF THE TELOMERE
9.4.1.2.2.2 PROCESSIVE SYNTHESIS ON THE C-STRAND OF THE TELOMERE
9.4.1.2.2.2.1 REMOVAL OF THE FLAP INTERMEDIATE FROM THE C-STRAND
9.4.1.2.2.3 TELOMERE C-STRAND SYNTHESIS INITIATION
9.4.2 NUCLEOSOME ASSEMBLY
9.4.2.1 DEPOSITION OF NEW CENPA-CONTAINING NUCLEOSOMES AT THE CENTROMERE
10 DISEASE
10.1 DISEASES OF GLYCOSYLATION
10.1.1 DISEASES ASSOCIATED WITH GLYCOSAMINOGLYCAN METABOLISM
10.1.1.1 "DEFECTIVE B4GALT7 CAUSES EDS, PROGEROID TYPE"
10.1.1.4 DEFECTIVE B3GAT3 CAUSES JDSSDHD
10.1.1.5 DEFECTIVE CHST3 CAUSES SEDCJD
10.1.1.6 "DEFECTIVE CHST14 CAUSES EDS, MUSCULOCONTRACTURAL TYPE"
10.1.1.7 DEFECTIVE CHSY1 CAUSES TPBS
10.1.1.8 DEFECTIVE CHST6 CAUSES MCDC1
10.1.1.10 DEFECTIVE EXT2 CAUSES EXOSTOSES 2
10.1.1.11 DEFECTIVE ST3GAL3 CAUSES MCT12 AND EIEE15
10.1.1.12 DEFECTIVE B4GALT1 CAUSES B4GALT1-CDG (CDG-2D)
10.1.1.14 "DEFECTIVE EXT1 CAUSES EXOSTOSES 1, TRPS2 AND CHDS"
10.1.1.15 DEFECTIVE B3GALT6 CAUSES EDSP2 AND SEMDJL1
10.1.3 DISEASES ASSOCIATED WITH O-GLYCOSYLATION OF PROTEINS
10.1.3.1 DEFECTIVE GALNT3 CAUSES FAMILIAL HYPERPHOSPHATEMIC TUMORAL CALCINOSIS (HFTC)
10.1.3.3 "DEFECTIVE POMGNT1 CAUSES MDDGA3, MDDGB3 AND MDDGC3"
10.1.3.4 "DEFECTIVE POMT2 CAUSES MDDGA2, MDDGB2 AND MDDGC2"
10.1.3.5 DEFECTIVE LFNG CAUSES SCDO3
10.1.3.6 DEFECTIVE C1GALT1C1 CAUSES TN POLYAGGLUTINATION SYNDROME (TNPS)
10.1.3.7 "DEFECTIVE POMT1 CAUSES MDDGA1, MDDGB1 AND MDDGC1"
10.1.3.8 DEFECTIVE B3GALTL CAUSES PETERS-PLUS SYNDROME (PPS)
10.1.3.9 DEFECTIVE GALNT12 CAUSES COLORECTAL CANCER 1 (CRCS1)
10.2 DISEASES OF IMMUNE SYSTEM
10.2.1 DISEASES ASSOCIATED WITH THE TLR SIGNALING CASCADE
10.2.1.1 TLR3 DEFICIENCY - HSE
10.2.1.2 UNC93B1 DEFICIENCY - HSE
10.2.1.3 MYD88 DEFICIENCY (TLR2/4)
10.2.1.4 TICAM1 DEFICIENCY - HSE
10.2.1.5 TRAF3 DEFICIENCY - HSE
10.2.1.6 IKBKB DEFICIENCY CAUSES SCID
10.2.1.7 MYD88 DEFICIENCY (TLR5)
10.2.1.8 IKBKG DEFICIENCY CAUSES ANHIDROTIC ECTODERMAL DYSPLASIA WITH IMMUNODEFICIENCY (EDA-ID) (VIA TLR)
10.2.1.9 IKBA VARIANT LEADS TO EDA-ID
10.2.1.10 IRAK4 DEFICIENCY (TLR5)
10.2.1.11 IRAK4 DEFICIENCY (TLR2/4)
10.3 DISEASES OF MISMATCH REPAIR (MMR)
10.3.1 DEFECTIVE MISMATCH REPAIR ASSOCIATED WITH MLH1
10.3.2 DEFECTIVE MISMATCH REPAIR ASSOCIATED WITH MSH3
10.3.3 DEFECTIVE MISMATCH REPAIR ASSOCIATED WITH MSH2
10.3.4 DEFECTIVE MISMATCH REPAIR ASSOCIATED WITH MSH6
10.3.5 DEFECTIVE MISMATCH REPAIR ASSOCIATED WITH PMS2
10.4 DISORDERS OF TRANSMEMBRANE TRANSPORTERS
10.4.1 ABC TRANSPORTER DISORDERS
10.4.1.4 DEFECTIVE CFTR CAUSES CYSTIC FIBROSIS
10.4.1.10 DEFECTIVE ABCC8 CAN CAUSE HYPOGLYCEMIAS AND HYPERGLYCEMIAS
10.4.2 SLC TRANSPORTER DISORDERS
10.4.2.22 "DEFECTIVE SLCO1B3 CAUSES HYPERBILIRUBINEMIA, ROTOR TYPE (HBLRR)"
10.4.2.50 "DEFECTIVE AVP DOES NOT BIND AVPR1A,B AND CAUSES NEUROHYPOPHYSEAL DIABETES INSIPIDUS (NDI)"
10.4.2.53 DEFECTIVE TPR MAY CONFER SUSCEPTIBILITY TOWARDS THYROID PAPILLARY CARCINOMA (TPC)
10.4.2.56 "DEFECTIVE SLCO1B1 CAUSES HYPERBILIRUBINEMIA, ROTOR TYPE (HBLRR)"
10.4.2.72 DEFECTIVE AVP DOES NOT BIND AVPR2 AND CAUSES NEUROHYPOPHYSEAL DIABETES INSIPIDUS (NDI)
10.5 DISEASES OF SIGNAL TRANSDUCTION
10.5.1 SIGNALING BY FGFR IN DISEASE
10.5.1.1 SIGNALING BY FGFR2 IN DISEASE
10.5.1.1.1 FGFR2 MUTANT RECEPTOR ACTIVATION
10.5.1.1.1.1 SIGNALING BY FGFR2 AMPLIFICATION MUTANTS
10.5.1.1.1.2 ACTIVATED POINT MUTANTS OF FGFR2
10.5.1.1.1.3 SIGNALING BY FGFR2 IIIA TM
10.5.1.1.1.4 SIGNALING BY FGFR2 FUSIONS
10.5.1.2 SIGNALING BY FGFR4 IN DISEASE
10.5.1.2.1 FGFR4 MUTANT RECEPTOR ACTIVATION
10.5.1.3 SIGNALING BY FGFR1 IN DISEASE
10.5.1.3.1 FGFR1 MUTANT RECEPTOR ACTIVATION
10.5.1.3.1.1 SIGNALING BY CYTOSOLIC FGFR1 FUSION MUTANTS
10.5.1.3.1.2 SIGNALING BY FGFR1 AMPLIFICATION MUTANTS
10.5.1.3.1.3 SIGNALING BY ACTIVATED POINT MUTANTS OF FGFR1
10.5.1.3.1.4 SIGNALING BY PLASMA MEMBRANE FGFR1 FUSIONS
10.5.1.4 SIGNALING BY FGFR3 IN DISEASE
10.5.1.4.1 SIGNALING BY FGFR3 FUSIONS IN CANCER
10.5.1.4.2 SIGNALING BY FGFR3 POINT MUTANTS IN CANCER
10.5.1.4.2.1 FGFR3 MUTANT RECEPTOR ACTIVATION
10.5.1.4.2.1.1 SIGNALING BY ACTIVATED POINT MUTANTS OF FGFR3
10.5.1.4.2.1.2 T(4;14) TRANSLOCATIONS OF FGFR3
10.5.2 SIGNALING BY EGFR IN CANCER
10.5.2.1 SIGNALING BY EGFRVIII IN CANCER
10.5.2.1.1 CONSTITUTIVE SIGNALING BY EGFRVIII
10.5.2.2 SIGNALING BY LIGAND-RESPONSIVE EGFR VARIANTS IN CANCER
10.5.2.2.1 CONSTITUTIVE SIGNALING BY LIGAND-RESPONSIVE EGFR CANCER VARIANTS
10.5.2.3 SIGNALING BY OVEREXPRESSED WILD-TYPE EGFR IN CANCER
10.5.2.3.1 INHIBITION OF SIGNALING BY OVEREXPRESSED EGFR
10.5.3 PI3K/AKT SIGNALING IN CANCER
10.5.3.1 CONSTITUTIVE SIGNALING BY ABERRANT PI3K IN CANCER
10.5.3.2 CONSTITUTIVE SIGNALING BY AKT1 E17K IN CANCER
10.5.4 DISEASES ASSOCIATED WITH VISUAL TRANSDUCTION
10.5.4.1 RETINOID CYCLE DISEASE EVENTS
10.5.4.1.1 "BIOSYNTHESIS OF A2E, IMPLICATED IN RETINAL DEGRADATION"
10.5.4.2 RETINOID METABOLISM DISEASE EVENTS
10.5.5 SIGNALING BY NOTCH1 IN CANCER
10.5.5.1 SIGNALING BY NOTCH1 PEST DOMAIN MUTANTS IN CANCER
10.5.5.1.1 CONSTITUTIVE SIGNALING BY NOTCH1 PEST DOMAIN MUTANTS
10.5.5.2 FBXW7 MUTANTS AND NOTCH1 IN CANCER
10.5.5.2.1 LOSS OF FUNCTION OF FBXW7 IN CANCER AND NOTCH1 SIGNALING
10.5.5.3 SIGNALING BY NOTCH1 T(7;9)(NOTCH1:M1580_K2555) TRANSLOCATION MUTANT
10.5.5.3.1 CONSTITUTIVE SIGNALING BY NOTCH1 T(7;9)(NOTCH1:M1580_K2555) TRANSLOCATION MUTANT
10.5.5.4 SIGNALING BY NOTCH1 HD DOMAIN MUTANTS IN CANCER
10.5.5.4.1 CONSTITUTIVE SIGNALING BY NOTCH1 HD DOMAIN MUTANTS
10.5.5.5 SIGNALING BY NOTCH1 HD+PEST DOMAIN MUTANTS IN CANCER
10.5.5.5.1 CONSTITUTIVE SIGNALING BY NOTCH1 HD+PEST DOMAIN MUTANTS
10.5.6 SIGNALING BY TGF-BETA RECEPTOR COMPLEX IN CANCER
10.5.6.1 LOSS OF FUNCTION OF SMAD4 IN CANCER
10.5.6.1.1 SMAD4 MH2 DOMAIN MUTANTS IN CANCER
10.5.6.2 LOSS OF FUNCTION OF SMAD2/3 IN CANCER
10.5.6.2.1 SMAD2/3 PHOSPHORYLATION MOTIF MUTANTS IN CANCER
10.5.6.2.2 SMAD2/3 MH2 DOMAIN MUTANTS IN CANCER
10.5.6.3 LOSS OF FUNCTION OF TGFBR2 IN CANCER
10.5.6.3.1 TGFBR2 MSI FRAMESHIFT MUTANTS IN CANCER
10.5.6.3.2 TGFBR2 KINASE DOMAIN MUTANTS IN CANCER
10.5.6.4 LOSS OF FUNCTION OF TGFBR1 IN CANCER
10.5.6.4.1 TGFBR1 KD MUTANTS IN CANCER
10.5.6.4.2 TGFBR1 LBD MUTANTS IN CANCER
10.5.7 SIGNALING BY WNT IN CANCER
10.5.7.1 "AXIN MUTANTS DESTABILIZE THE DESTRUCTION COMPLEX, ACTIVATING WNT SIGNALING"
10.5.7.1.1 AXIN MISSENSE MUTANTS DESTABILIZE THE DESTRUCTION COMPLEX
10.5.7.1.2 DELETIONS IN THE AXIN GENES IN HEPATOCELLULAR CARCINOMA RESULT IN ELEVATED WNT SIGNALING
10.5.7.2 PHOSPHORYLATION SITE MUTANTS OF CTNNB1 ARE NOT TARGETED TO THE PROTEASOME BY THE DESTRUCTION COMPLEX
10.5.7.2.1 S33 MUTANTS OF BETA-CATENIN AREN'T PHOSPHORYLATED
10.5.7.2.2 S37 MUTANTS OF BETA-CATENIN AREN'T PHOSPHORYLATED
10.5.7.2.3 S45 MUTANTS OF BETA-CATENIN AREN'T PHOSPHORYLATED
10.5.7.2.4 T41 MUTANTS OF BETA-CATENIN AREN'T PHOSPHORYLATED
10.5.7.3 TRUNCATED APC MUTANTS DESTABILIZE THE DESTRUCTION COMPLEX
10.5.7.3.1 APC TRUNCATION MUTANTS ARE NOT K63 POLYUBIQUITINATED
10.5.7.3.2 APC TRUNCATION MUTANTS HAVE IMPAIRED AXIN BINDING
10.5.7.4 AMER1 MUTANTS DESTABILIZE THE DESTRUCTION COMPLEX
10.5.7.4.1 DELETIONS IN THE AMER1 GENE DESTABILIZE THE DESTRUCTION COMPLEX
10.5.7.4.2 TRUNCATIONS OF AMER1 DESTABILIZE THE DESTRUCTION COMPLEX
10.5.7.5 TCF7L2 MUTANTS DON'T BIND CTBP
10.5.7.6 MISSPLICED GSK3BETA MUTANTS STABILIZE BETA-CATENIN
10.5.7.7 MISSPLICED LRP5 MUTANTS HAVE ENHANCED BETA-CATENIN-DEPENDENT SIGNALING
10.5.7.8 WNT LIGAND SECRETION IS ABROGATED BY THE PORCN INHIBITOR LGK974
10.5.7.9 RNF MUTANTS SHOW ENHANCED WNT SIGNALING AND PROLIFERATION
10.5.7.10 "XAV939 INHIBITS TANKYRASE, STABILIZING AXIN"
10.5.8 HH MUTANTS ABROGATE LIGAND SECRETION
10.5.8.1 HH MUTANTS THAT DON'T UNDERGO AUTOCATALYTIC PROCESSING ARE DEGRADED BY ERAD
10.5.8.2 HHAT G278V ABROGATES PALMITOYLATION OF HH-NP
10.5.9 ONCOGENIC MAPK SIGNALING
10.5.9.1 SIGNALING BY MODERATE KINASE ACTIVITY BRAF MUTANTS
10.5.9.2 SIGNALING BY HIGH-KINASE ACTIVITY BRAF MUTANTS
10.5.9.3 SIGNALING BY RAS MUTANTS
10.5.9.4 SIGNALING BY BRAF AND RAF FUSIONS
10.5.9.5 RAS SIGNALING DOWNSTREAM OF NF1 LOSS-OF-FUNCTION VARIANTS
10.5.9.6 PARADOXICAL ACTIVATION OF RAF SIGNALING BY KINASE INACTIVE BRAF
10.6 INFECTIOUS DISEASE
10.6.1 LATENT INFECTION OF HOMO SAPIENS WITH MYCOBACTERIUM TUBERCULOSIS
10.6.1.1 RESPONSE OF MTB TO PHAGOCYTOSIS
10.6.1.1.1 TOLERANCE OF REACTIVE OXYGEN PRODUCED BY MACROPHAGES
10.6.1.1.2 MTB IRON ASSIMILATION BY CHELATION
10.6.1.1.3 TOLERANCE BY MTB TO NITRIC OXIDE PRODUCED BY MACROPHAGES
10.6.1.1.4 CELL REDOX HOMEOSTASIS
10.6.2 HIV INFECTION
10.6.2.1 HIV LIFE CYCLE
10.6.2.1.1 EARLY PHASE OF HIV LIFE CYCLE
10.6.2.1.1.1 UNCOATING OF THE HIV VIRION
10.6.2.1.1.2 REVERSE TRANSCRIPTION OF HIV RNA
10.6.2.1.1.2.1 MINUS-STRAND DNA SYNTHESIS
10.6.2.1.1.2.2 PLUS-STRAND DNA SYNTHESIS
10.6.2.1.1.3 INTEGRATION OF PROVIRUS
10.6.2.1.1.3.1 2-LTR CIRCLE FORMATION
10.6.2.1.1.3.2 INTEGRATION OF VIRAL DNA INTO HOST GENOMIC DNA
10.6.2.1.1.3.3 AUTOINTEGRATION RESULTS IN VIRAL DNA CIRCLES
10.6.2.1.1.4 BINDING AND ENTRY OF HIV VIRION
10.6.2.1.2 LATE PHASE OF HIV LIFE CYCLE
10.6.2.1.2.1 BUDDING AND MATURATION OF HIV VIRION
10.6.2.1.2.2 REV-MEDIATED NUCLEAR EXPORT OF HIV RNA
10.6.2.1.2.3 TRANSCRIPTION OF THE HIV GENOME
10.6.2.1.2.3.1 FORMATION OF HIV ELONGATION COMPLEX IN THE ABSENCE OF HIV TAT
10.6.2.1.2.3.2 RNA POL II CTD PHOSPHORYLATION AND INTERACTION WITH CE DURING HIV INFECTION
10.6.2.1.2.3.3 HIV TRANSCRIPTION INITIATION
10.6.2.1.2.3.4 RNA POLYMERASE II HIV PROMOTER ESCAPE
10.6.2.1.2.3.5 HIV TRANSCRIPTION ELONGATION
10.6.2.1.2.3.5.1 FORMATION OF THE HIV-1 EARLY ELONGATION COMPLEX
10.6.2.1.2.3.5.2 ABORTIVE ELONGATION OF HIV-1 TRANSCRIPT IN THE ABSENCE OF TAT
10.6.2.1.2.3.5.3 TAT-MEDIATED ELONGATION OF THE HIV-1 TRANSCRIPT
10.6.2.1.2.3.5.3.1 FORMATION OF HIV-1 ELONGATION COMPLEX CONTAINING HIV-1 TAT
10.6.2.1.2.3.6 PAUSING AND RECOVERY OF TAT-MEDIATED HIV ELONGATION
10.6.2.1.2.3.7 TAT-MEDIATED HIV ELONGATION ARREST AND RECOVERY
10.6.2.1.2.3.8 HIV ELONGATION ARREST AND RECOVERY
10.6.2.1.2.3.9 PAUSING AND RECOVERY OF HIV ELONGATION
10.6.2.1.2.4 ASSEMBLY OF THE HIV VIRION
10.6.2.1.2.4.1 SYNTHESIS AND PROCESSING OF ENV AND VPU
10.6.2.1.2.4.2 "SYNTHESIS AND PROCESSING OF GAG, GAGPOL POLYPROTEINS"
10.6.2.1.2.4.2.1 MEMBRANE BINDING AND TARGETTING OF GAG PROTEINS
10.6.2.2 HOST INTERACTIONS OF HIV FACTORS
10.6.2.2.1 THE ROLE OF NEF IN HIV-1 REPLICATION AND DISEASE PATHOGENESIS
10.6.2.2.1.1 NEF-MEDIATES DOWN MODULATION OF CELL SURFACE RECEPTORS BY RECRUITING THEM TO CLATHRIN ADAPTERS
10.6.2.2.1.1.1 NEF MEDIATED DOWNREGULATION OF CD28 CELL SURFACE EXPRESSION
10.6.2.2.1.1.2 NEF MEDIATED DOWNREGULATION OF MHC CLASS I COMPLEX CELL SURFACE EXPRESSION
10.6.2.2.1.1.3 NEF MEDIATED CD4 DOWN-REGULATION
10.6.2.2.1.1.4 NEF MEDIATED CD8 DOWN-REGULATION
10.6.2.2.1.2 NEF AND SIGNAL TRANSDUCTION
10.6.2.2.2 INTERACTIONS OF VPR WITH HOST CELLULAR PROTEINS
10.6.2.2.2.1 VPR-MEDIATED INDUCTION OF APOPTOSIS BY MITOCHONDRIAL OUTER MEMBRANE PERMEABILIZATION
10.6.2.2.2.2 VPR-MEDIATED NUCLEAR IMPORT OF PICS
10.6.2.2.3 INTERACTIONS OF TAT WITH HOST CELLULAR PROTEINS
10.6.2.2.4 INTERACTIONS OF REV WITH HOST CELLULAR PROTEINS
10.6.2.2.4.1 REV-MEDIATED NUCLEAR EXPORT OF HIV RNA
10.6.2.2.4.2 NUCLEAR IMPORT OF REV PROTEIN
10.6.2.2.5 VPU MEDIATED DEGRADATION OF CD4
10.6.2.2.6 VIF-MEDIATED DEGRADATION OF APOBEC3G
10.6.2.2.7 APOBEC3G MEDIATED RESISTANCE TO HIV-1 INFECTION
10.6.3 INFLUENZA INFECTION
10.6.3.1 HOST INTERACTIONS WITH INFLUENZA FACTORS
10.6.3.1.1 NS1 MEDIATED EFFECTS ON HOST PATHWAYS
10.6.3.1.1.1 INHIBITION OF INTERFERON SYNTHESIS
10.6.3.1.1.1.1 INHIBITION OF IFN-BETA
10.6.3.1.1.2 INHIBITION OF HOST MRNA PROCESSING AND RNA SILENCING
10.6.3.1.1.3 INHIBITION OF PKR
10.6.3.1.2 INFLUENZA VIRUS INDUCED APOPTOSIS
10.6.3.2 INFLUENZA LIFE CYCLE
10.6.3.2.1 VIRUS ASSEMBLY AND RELEASE
10.6.3.2.1.1 RELEASE
10.6.3.2.1.2 BUDDING
10.6.3.2.1.3 PACKAGING OF EIGHT RNA SEGMENTS
10.6.3.2.1.4 ASSEMBLY OF VIRAL COMPONENTS AT THE BUDDING SITE
10.6.3.2.1.4.1 "TRANSPORT OF HA TRIMER, NA TETRAMER AND M2 TETRAMER FROM THE ENDOPLASMIC RETICULUM TO THE GOLGI APPARATUS"
10.6.3.2.2 FUSION AND UNCOATING OF THE INFLUENZA VIRION
10.6.3.2.2.1 FUSION OF THE INFLUENZA VIRION TO THE HOST CELL ENDOSOME
10.6.3.2.2.2 UNCOATING OF THE INFLUENZA VIRION
10.6.3.2.3 TRANSPORT OF RIBONUCLEOPROTEINS INTO THE HOST NUCLEUS
10.6.3.2.4 INFLUENZA VIRAL RNA TRANSCRIPTION AND REPLICATION
10.6.3.2.4.1 VIRAL MESSENGER RNA SYNTHESIS
10.6.3.2.4.2 VRNA SYNTHESIS
10.6.3.2.4.3 VIRAL MRNA TRANSLATION
10.6.3.2.4.4 CRNA SYNTHESIS
10.6.3.2.4.5 VRNP ASSEMBLY
10.6.3.2.5 EXPORT OF VIRAL RIBONUCLEOPROTEINS FROM NUCLEUS
10.6.3.2.5.1 VIRAL RNP COMPLEXES IN THE HOST CELL NUCLEUS
10.6.3.2.5.2 NEP/NS2 INTERACTS WITH THE CELLULAR EXPORT MACHINERY
10.6.3.2.6 ENTRY OF INFLUENZA VIRION INTO HOST CELL VIA ENDOCYTOSIS
10.6.4 UPTAKE AND ACTIONS OF BACTERIAL TOXINS
10.6.4.1 NEUROTOXICITY OF CLOSTRIDIUM TOXINS
10.6.4.1.1 TOXICITY OF BOTULINUM TOXIN TYPE D (BONT/D)
10.6.4.1.2 TOXICITY OF BOTULINUM TOXIN TYPE B (BONT/B)
10.6.4.1.3 TOXICITY OF BOTULINUM TOXIN TYPE A (BONT/A)
10.6.4.1.4 TOXICITY OF BOTULINUM TOXIN TYPE C (BONT/C)
10.6.4.1.5 TOXICITY OF BOTULINUM TOXIN TYPE F (BONT/F)
10.6.4.1.6 TOXICITY OF TETANUS TOXIN (TENT)
10.6.4.1.7 TOXICITY OF BOTULINUM TOXIN TYPE G (BONT/G)
10.6.4.1.8 TOXICITY OF BOTULINUM TOXIN TYPE E (BONT/E)
10.6.4.2 UPTAKE AND FUNCTION OF ANTHRAX TOXINS
10.6.4.3 UPTAKE AND FUNCTION OF DIPHTHERIA TOXIN
10.6.4.4 INTESTINAL INFECTIOUS DISEASES
10.6.5 LISTERIA MONOCYTOGENES ENTRY INTO HOST CELLS
10.6.5.1 INLB-MEDIATED ENTRY OF LISTERIA MONOCYTOGENES INTO HOST CELL
10.6.5.2 INLA-MEDIATED ENTRY OF LISTERIA MONOCYTOGENES INTO HOST CELLS
10.7 DISEASES OF METABOLISM
10.7.2 ABNORMAL CONVERSION OF 2-OXOGLUTARATE TO 2-HYDROXYGLUTARATE
10.7.3 DEFECTS IN VITAMIN AND COFACTOR METABOLISM
10.7.3.1 DEFECTS IN COBALAMIN (B12) METABOLISM
10.7.3.1.1 DEFECTIVE TCN2 CAUSES HEREDITARY MEGALOBLASTIC ANEMIA
10.7.3.1.2 DEFECTIVE GIF CAUSES INTRINSIC FACTOR DEFICIENCY
10.7.3.1.4 DEFECTIVE AMN CAUSES HEREDITARY MEGALOBLASTIC ANEMIA 1
10.7.3.1.5 DEFECTIVE CUBN CAUSES HEREDITARY MEGALOBLASTIC ANEMIA 1
10.7.3.1.6 DEFECTIVE MTRR CAUSES METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA TYPE CBLE
10.7.3.1.7 DEFECTIVE MTR CAUSES METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA TYPE CBLG
10.7.3.1.9 DEFECTIVE MMADHC CAUSES METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA TYPE CBLD
10.7.3.1.10 DEFECTIVE MMACHC CAUSES METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA TYPE CBLC
10.7.3.1.11 DEFECTIVE MMAA CAUSES METHYLMALONIC ACIDURIA TYPE CBLA
10.7.3.1.13 DEFECTIVE CD320 CAUSES METHYLMALONIC ACIDURIA
10.7.3.2 DEFECTS IN BIOTIN (BTN) METABOLISM
10.7.3.2.2 DEFECTIVE HLCS CAUSES MULTIPLE CARBOXYLASE DEFICIENCY
10.7.4 METABOLIC DISORDERS OF BIOLOGICAL OXIDATION ENZYMES
10.7.4.26 "DEFECTIVE CYP11A1 CAUSES ADRENAL INSUFFICIENCY, CONGENITAL, WITH 46,XY SEX REVERSAL (AICSR)"
10.7.4.30 DEFECTIVE ACTH CAUSES OBESITY AND PRO-OPIOMELANOCORTININ DEFICIENCY (POMCD)
10.7.5 DISEASES OF CARBOHYDRATE METABOLISM
10.7.5.2 GLYCOGEN STORAGE DISEASES
10.7.5.2.4 MYOCLONIC EPILEPSY OF LAFORA
10.7.5.2.5 GLYCOGEN STORAGE DISEASE TYPE XV (GYG1)
10.7.5.2.6 GLYCOGEN STORAGE DISEASE TYPE 0 (MUSCLE GYS1)
10.7.5.2.7 GLYCOGEN STORAGE DISEASE TYPE 0 (LIVER GYS2)
10.7.5.2.8 GLYCOGEN STORAGE DISEASE TYPE IV (GBE1)
10.7.5.2.9 GLYCOGEN STORAGE DISEASE TYPE II (GAA)
10.7.6 DISEASES ASSOCIATED WITH SURFACTANT METABOLISM
10.7.6.2 DEFECTIVE SFTPA2 CAUSES IDIOPATHIC PULMONARY FIBROSIS (IPF)
10.7.6.3 DEFECTIVE PRO-SFTPB CAUSES PULMONARY SURFACTANT METABOLISM DYSFUNCTION 1 (SMDP1) AND RESPIRATORY DISTRESS SYNDROME (RDS)
10.7.6.4 DEFECTIVE PRO-SFTPC CAUSES PULMONARY SURFACTANT METABOLISM DYSFUNCTION 2 (SMDP2) AND RESPIRATORY DISTRESS SYNDROME (RDS)
10.7.6.6 DEFECTIVE CSF2RB CAUSES PULMONARY SURFACTANT METABOLISM DYSFUNCTION 5 (SMDP5)
10.7.6.7 DEFECTIVE CSF2RA CAUSES PULMONARY SURFACTANT METABOLISM DYSFUNCTION 4 (SMDP4)
10.8 NEURODEGENERATIVE DISEASES
10.8.1 DEREGULATED CDK5 TRIGGERS MULTIPLE NEURODEGENERATIVE PATHWAYS IN ALZHEIMER'S DISEASE MODELS
10.9 PERVASIVE DEVELOPMENTAL DISORDERS
10.9.1 LOSS OF FUNCTION OF MECP2 IN RETT SYNDROME
10.9.1.1 LOSS OF MECP2 BINDING ABILITY TO 5HMC-DNA
10.9.1.2 LOSS OF PHOSPHORYLATION OF MECP2 AT T308
10.9.1.3 LOSS OF MECP2 BINDING ABILITY TO THE NCOR/SMRT COMPLEX
10.9.1.4 LOSS OF MECP2 BINDING ABILITY TO 5MC-DNA
10.1 DISEASES OF BASE EXCISION REPAIR
10.10.1 DEFECTIVE BASE EXCISION REPAIR ASSOCIATED WITH MUTYH
10.10.1.1 DEFECTIVE MUTYH SUBSTRATE BINDING
10.10.1.2 DEFECTIVE MUTYH SUBSTRATE PROCESSING
11 IMMUNE SYSTEM
11.1 CYTOKINE SIGNALING IN IMMUNE SYSTEM
11.1.1 PROLACTIN RECEPTOR SIGNALING
11.1.2 SIGNALING BY INTERLEUKINS
11.1.2.1 INTERLEUKIN-7 SIGNALING
11.1.2.2 INTERLEUKIN-1 FAMILY SIGNALING
11.1.2.2.1 INTERLEUKIN-1 PROCESSING
11.1.2.2.2 INTERLEUKIN-38 SIGNALING
11.1.2.2.3 INTERLEUKIN-37 SIGNALING
11.1.2.2.4 INTERLEUKIN-18 SIGNALING
11.1.2.2.5 INTERLEUKIN-36 PATHWAY
11.1.2.2.6 INTERLEUKIN-33 SIGNALING
11.1.2.2.7 INTERLEUKIN-1 SIGNALING
11.1.2.2.7.1 TAK1 ACTIVATES NFKB BY PHOSPHORYLATION AND ACTIVATION OF IKKS COMPLEX
11.1.2.2.7.2 MAP3K8 (TPL2)-DEPENDENT MAPK1/3 ACTIVATION
11.1.2.3 INTERLEUKIN-12 FAMILY SIGNALING
11.1.2.3.1 INTERLEUKIN-35 SIGNALLING
11.1.2.3.2 INTERLEUKIN-12 SIGNALING
11.1.2.3.2.1 GENE AND PROTEIN EXPRESSION BY JAK-STAT SIGNALING AFTER INTERLEUKIN-12 STIMULATION
11.1.2.3.3 INTERLEUKIN-23 SIGNALING
11.1.2.3.4 INTERLEUKIN-27 SIGNALING
11.1.2.4 INTERLEUKIN-17 SIGNALING
11.1.2.4.1 MAP KINASE ACTIVATION
11.1.2.4.1.1 MAPK TARGETS/ NUCLEAR EVENTS MEDIATED BY MAP KINASES
11.1.2.4.1.1.1 ERK/MAPK TARGETS
11.1.2.4.1.1.1.1 ERKS ARE INACTIVATED
11.1.2.4.1.1.2 CREB PHOSPHORYLATION
11.1.2.4.1.1.3 ACTIVATION OF THE AP-1 FAMILY OF TRANSCRIPTION FACTORS
11.1.2.4.1.2 ACTIVATED TAK1 MEDIATES P38 MAPK ACTIVATION
11.1.2.4.1.3 JNK (C-JUN KINASES) PHOSPHORYLATION AND  ACTIVATION MEDIATED BY ACTIVATED HUMAN TAK1
11.1.2.4.1.4 MAP3K8 (TPL2)-DEPENDENT MAPK1/3 ACTIVATION
11.1.2.5 OTHER INTERLEUKIN SIGNALING
11.1.2.6 INTERLEUKIN-2 FAMILY SIGNALING
11.1.2.6.1 INTERLEUKIN-15 SIGNALING
11.1.2.6.2 INTERLEUKIN-9 SIGNALING
11.1.2.6.3 INTERLEUKIN-2 SIGNALING
11.1.2.6.4 INTERLEUKIN-21 SIGNALING
11.1.2.6.5 INTERLEUKIN RECEPTOR SHC SIGNALING
11.1.2.7 "INTERLEUKIN-3, INTERLEUKIN-5 AND GM-CSF SIGNALING"
11.1.2.7.1 INTERLEUKIN RECEPTOR SHC SIGNALING
11.1.2.7.2 REGULATION OF SIGNALING BY CBL
11.1.2.8 INTERLEUKIN-6 FAMILY SIGNALING
11.1.2.8.1 INTERLEUKIN-6 SIGNALING
11.1.2.8.2 IL-6-TYPE CYTOKINE RECEPTOR LIGAND INTERACTIONS
11.1.2.9 INTERLEUKIN-10 SIGNALING
11.1.2.10 INTERLEUKIN-4 AND INTERLEUKIN-13 SIGNALING
11.1.2.11 INTERLEUKIN-20 FAMILY SIGNALING
11.1.3 TNFR2 NON-CANONICAL NF-KB PATHWAY
11.1.3.1 TNFS BIND THEIR PHYSIOLOGICAL RECEPTORS
11.1.3.2 NIK-->NONCANONICAL NF-KB SIGNALING
11.1.3.3 TNF RECEPTOR SUPERFAMILY (TNFSF) MEMBERS MEDIATING NON-CANONICAL NF-KB PATHWAY
11.1.4 INTERFERON SIGNALING
11.1.4.1 ANTIVIRAL MECHANISM BY IFN-STIMULATED GENES
11.1.4.1.1 ISG15 ANTIVIRAL MECHANISM
11.1.4.1.2 OAS ANTIVIRAL RESPONSE
11.1.4.2 INTERFERON GAMMA SIGNALING
11.1.4.2.1 REGULATION OF IFNG SIGNALING
11.1.4.3 INTERFERON ALPHA/BETA SIGNALING
11.1.4.3.1 REGULATION OF IFNA SIGNALING
11.1.5 GROWTH HORMONE RECEPTOR SIGNALING
11.2 ADAPTIVE IMMUNE SYSTEM
11.2.1 IMMUNOREGULATORY INTERACTIONS BETWEEN A LYMPHOID AND A NON-LYMPHOID CELL
11.2.2 TCR SIGNALING
11.2.2.1 DOWNSTREAM TCR SIGNALING
11.2.2.2 PHOSPHORYLATION OF CD3 AND TCR ZETA CHAINS
11.2.2.3 TRANSLOCATION OF ZAP-70 TO IMMUNOLOGICAL SYNAPSE
11.2.2.4 GENERATION OF SECOND MESSENGER MOLECULES
11.2.3 MHC CLASS II ANTIGEN PRESENTATION
11.2.4 COSTIMULATION BY THE CD28 FAMILY
11.2.4.1 CD28 CO-STIMULATION
11.2.4.1.1 CD28 DEPENDENT PI3K/AKT SIGNALING
11.2.4.1.2 CD28 DEPENDENT VAV1 PATHWAY
11.2.4.2 CTLA4 INHIBITORY SIGNALING
11.2.4.3 PD-1 SIGNALING
11.2.5 RAP1 SIGNALLING
11.2.6 BUTYROPHILIN (BTN) FAMILY INTERACTIONS
11.2.7 CLASS I MHC MEDIATED ANTIGEN PROCESSING & PRESENTATION
11.2.7.1 ANTIGEN PROCESSING-CROSS PRESENTATION
11.2.7.1.1 CROSS-PRESENTATION OF PARTICULATE EXOGENOUS ANTIGENS (PHAGOSOMES)
11.2.7.1.2 ER-PHAGOSOME PATHWAY
11.2.7.1.3 ENDOSOMAL/VACUOLAR PATHWAY
11.2.7.1.4 CROSS-PRESENTATION OF SOLUBLE EXOGENOUS ANTIGENS (ENDOSOMES)
11.2.7.2 ANTIGEN PROCESSING: UBIQUITINATION & PROTEASOME DEGRADATION
11.2.7.3 "ANTIGEN PRESENTATION: FOLDING, ASSEMBLY AND PEPTIDE LOADING OF CLASS I MHC"
11.2.8 SIGNALING BY THE B CELL RECEPTOR (BCR)
11.2.8.1 DOWNSTREAM SIGNALING EVENTS OF B CELL RECEPTOR (BCR)
11.2.8.1.1 ACTIVATION OF NF-KAPPAB IN B CELLS
11.2.8.1.2 ACTIVATION OF RAS IN B CELLS
11.2.8.1.3 CALCINEURIN ACTIVATES NFAT
11.2.8.2 CD22 MEDIATED BCR REGULATION
11.2.8.3 ANTIGEN ACTIVATES B CELL RECEPTOR (BCR) LEADING TO GENERATION OF SECOND MESSENGERS
11.3 INNATE IMMUNE SYSTEM
11.3.1 "ROS, RNS PRODUCTION IN PHAGOCYTES"
11.3.1.1 EVENTS ASSOCIATED WITH PHAGOCYTOLYTIC ACTIVITY OF PMN CELLS
11.3.2 COMPLEMENT CASCADE
11.3.2.1 INITIAL TRIGGERING OF COMPLEMENT
11.3.2.1.1 CREATION OF C4 AND C2 ACTIVATORS
11.3.2.1.1.1 LECTIN PATHWAY OF COMPLEMENT ACTIVATION
11.3.2.1.1.1.1 FICOLINS BIND TO REPETITIVE CARBOHYDRATE STRUCTURES ON THE TARGET CELL SURFACE
11.3.2.1.1.2 CLASSICAL ANTIBODY-MEDIATED COMPLEMENT ACTIVATION
11.3.2.1.2 ALTERNATIVE COMPLEMENT ACTIVATION
11.3.2.2 TERMINAL PATHWAY OF COMPLEMENT
11.3.2.3 ACTIVATION OF C3 AND C5
11.3.2.4 REGULATION OF COMPLEMENT CASCADE
11.3.3 "NUCLEOTIDE-BINDING DOMAIN, LEUCINE RICH REPEAT CONTAINING RECEPTOR (NLR) SIGNALING PATHWAYS"
11.3.3.1 NOD1/2 SIGNALING PATHWAY
11.3.3.2 INFLAMMASOMES
11.3.3.2.1 THE NLRP1 INFLAMMASOME
11.3.3.2.2 THE NLRP3 INFLAMMASOME
11.3.3.2.3 THE AIM2 INFLAMMASOME
11.3.3.2.4 THE IPAF INFLAMMASOME
11.3.4 TOLL-LIKE RECEPTOR CASCADES
11.3.4.1 TOLL LIKE RECEPTOR 4 (TLR4) CASCADE
11.3.4.1.1 TRANSFER OF LPS FROM LBP CARRIER TO CD14
11.3.4.1.2 MYD88:MAL(TIRAP) CASCADE INITIATED ON PLASMA MEMBRANE
11.3.4.1.2.1 TAK1 ACTIVATES NFKB BY PHOSPHORYLATION AND ACTIVATION OF IKKS COMPLEX
11.3.4.1.2.2 MAP KINASE ACTIVATION
11.3.4.1.2.2.1 MAPK TARGETS/ NUCLEAR EVENTS MEDIATED BY MAP KINASES
11.3.4.1.2.2.1.1 ERK/MAPK TARGETS
11.3.4.1.2.2.1.1.1 ERKS ARE INACTIVATED
11.3.4.1.2.2.1.2 CREB PHOSPHORYLATION
11.3.4.1.2.2.1.3 ACTIVATION OF THE AP-1 FAMILY OF TRANSCRIPTION FACTORS
11.3.4.1.2.2.2 ACTIVATED TAK1 MEDIATES P38 MAPK ACTIVATION
11.3.4.1.2.2.3 JNK (C-JUN KINASES) PHOSPHORYLATION AND  ACTIVATION MEDIATED BY ACTIVATED HUMAN TAK1
11.3.4.1.2.2.4 MAP3K8 (TPL2)-DEPENDENT MAPK1/3 ACTIVATION
11.3.4.1.2.3 IRAK1 RECRUITS IKK COMPLEX
11.3.4.1.2.4 IRAK2 MEDIATED ACTIVATION OF TAK1 COMPLEX
11.3.4.1.3 MYD88-INDEPENDENT TLR4 CASCADE
11.3.4.1.3.1 TRIF(TICAM1)-MEDIATED TLR4 SIGNALING
11.3.4.1.3.1.1 TRIF-MEDIATED PROGRAMMED CELL DEATH
11.3.4.1.3.1.2 TAK1 ACTIVATES NFKB BY PHOSPHORYLATION AND ACTIVATION OF IKKS COMPLEX
11.3.4.1.3.1.3 MAP KINASE ACTIVATION
11.3.4.1.3.1.3.1 MAPK TARGETS/ NUCLEAR EVENTS MEDIATED BY MAP KINASES
11.3.4.1.3.1.3.1.1 ERK/MAPK TARGETS
11.3.4.1.3.1.3.1.1.1 ERKS ARE INACTIVATED
11.3.4.1.3.1.3.1.2 CREB PHOSPHORYLATION
11.3.4.1.3.1.3.1.3 ACTIVATION OF THE AP-1 FAMILY OF TRANSCRIPTION FACTORS
11.3.4.1.3.1.3.2 ACTIVATED TAK1 MEDIATES P38 MAPK ACTIVATION
11.3.4.1.3.1.3.3 JNK (C-JUN KINASES) PHOSPHORYLATION AND  ACTIVATION MEDIATED BY ACTIVATED HUMAN TAK1
11.3.4.1.3.1.3.4 MAP3K8 (TPL2)-DEPENDENT MAPK1/3 ACTIVATION
11.3.4.1.3.1.4 ACTIVATION OF IRF3/IRF7 MEDIATED BY TBK1/IKK EPSILON
11.3.4.1.3.1.5 IKK COMPLEX RECRUITMENT MEDIATED BY RIP1
11.3.4.1.3.1.6 TRAF6-MEDIATED INDUCTION OF TAK1 COMPLEX WITHIN TLR4 COMPLEX
11.3.4.2 TRAFFICKING AND PROCESSING OF ENDOSOMAL TLR
11.3.4.3 TOLL LIKE RECEPTOR 9 (TLR9) CASCADE
11.3.4.3.1 MYD88 DEPENDENT CASCADE INITIATED ON ENDOSOME
11.3.4.3.1.1 TRAF6 MEDIATED IRF7 ACTIVATION IN TLR7/8 OR 9 SIGNALING
11.3.4.3.1.2 TRAF6 MEDIATED INDUCTION OF NFKB AND MAP KINASES UPON TLR7/8 OR 9 ACTIVATION
11.3.4.3.1.2.1 TAK1 ACTIVATES NFKB BY PHOSPHORYLATION AND ACTIVATION OF IKKS COMPLEX
11.3.4.3.1.2.2 MAP KINASE ACTIVATION
11.3.4.3.1.2.2.1 MAPK TARGETS/ NUCLEAR EVENTS MEDIATED BY MAP KINASES
11.3.4.3.1.2.2.1.1 ERK/MAPK TARGETS
11.3.4.3.1.2.2.1.1.1 ERKS ARE INACTIVATED
11.3.4.3.1.2.2.1.2 CREB PHOSPHORYLATION
11.3.4.3.1.2.2.1.3 ACTIVATION OF THE AP-1 FAMILY OF TRANSCRIPTION FACTORS
11.3.4.3.1.2.2.2 ACTIVATED TAK1 MEDIATES P38 MAPK ACTIVATION
11.3.4.3.1.2.2.3 JNK (C-JUN KINASES) PHOSPHORYLATION AND  ACTIVATION MEDIATED BY ACTIVATED HUMAN TAK1
11.3.4.3.1.2.2.4 MAP3K8 (TPL2)-DEPENDENT MAPK1/3 ACTIVATION
11.3.4.3.1.2.3 IRAK1 RECRUITS IKK COMPLEX UPON TLR7/8 OR 9 STIMULATION
11.3.4.3.1.2.4 IRAK2 MEDIATED ACTIVATION OF TAK1 COMPLEX UPON TLR7/8 OR 9 STIMULATION
11.3.4.4 TOLL LIKE RECEPTOR 10 (TLR10) CASCADE
11.3.4.4.1 MYD88 CASCADE INITIATED ON PLASMA MEMBRANE
11.3.4.4.1.1 TAK1 ACTIVATES NFKB BY PHOSPHORYLATION AND ACTIVATION OF IKKS COMPLEX
11.3.4.4.1.2 MAP KINASE ACTIVATION
11.3.4.4.1.2.1 MAPK TARGETS/ NUCLEAR EVENTS MEDIATED BY MAP KINASES
11.3.4.4.1.2.1.1 ERK/MAPK TARGETS
11.3.4.4.1.2.1.1.1 ERKS ARE INACTIVATED
11.3.4.4.1.2.1.2 CREB PHOSPHORYLATION
11.3.4.4.1.2.1.3 ACTIVATION OF THE AP-1 FAMILY OF TRANSCRIPTION FACTORS
11.3.4.4.1.2.2 ACTIVATED TAK1 MEDIATES P38 MAPK ACTIVATION
11.3.4.4.1.2.3 JNK (C-JUN KINASES) PHOSPHORYLATION AND  ACTIVATION MEDIATED BY ACTIVATED HUMAN TAK1
11.3.4.4.1.2.4 MAP3K8 (TPL2)-DEPENDENT MAPK1/3 ACTIVATION
11.3.4.4.1.3 IRAK1 RECRUITS IKK COMPLEX
11.3.4.4.1.4 IRAK2 MEDIATED ACTIVATION OF TAK1 COMPLEX
11.3.4.5 TOLL LIKE RECEPTOR 3 (TLR3) CASCADE
11.3.4.5.1 "TICAM1, RIP1-MEDIATED IKK COMPLEX RECRUITMENT"
11.3.4.5.2 TAK1 ACTIVATES NFKB BY PHOSPHORYLATION AND ACTIVATION OF IKKS COMPLEX
11.3.4.5.3 MAP KINASE ACTIVATION
11.3.4.5.3.1 MAPK TARGETS/ NUCLEAR EVENTS MEDIATED BY MAP KINASES
11.3.4.5.3.1.1 ERK/MAPK TARGETS
11.3.4.5.3.1.1.1 ERKS ARE INACTIVATED
11.3.4.5.3.1.2 CREB PHOSPHORYLATION
11.3.4.5.3.1.3 ACTIVATION OF THE AP-1 FAMILY OF TRANSCRIPTION FACTORS
11.3.4.5.3.2 ACTIVATED TAK1 MEDIATES P38 MAPK ACTIVATION
11.3.4.5.3.3 JNK (C-JUN KINASES) PHOSPHORYLATION AND  ACTIVATION MEDIATED BY ACTIVATED HUMAN TAK1
11.3.4.5.3.4 MAP3K8 (TPL2)-DEPENDENT MAPK1/3 ACTIVATION
11.3.4.5.4 TLR3-MEDIATED TICAM1-DEPENDENT PROGRAMMED CELL DEATH
11.3.4.5.5 TICAM1-DEPENDENT ACTIVATION OF IRF3/IRF7
11.3.4.5.6 "TICAM1,TRAF6-DEPENDENT INDUCTION OF TAK1 COMPLEX"
11.3.4.6 TOLL LIKE RECEPTOR 5 (TLR5) CASCADE
11.3.4.6.1 MYD88 CASCADE INITIATED ON PLASMA MEMBRANE
11.3.4.6.1.1 TAK1 ACTIVATES NFKB BY PHOSPHORYLATION AND ACTIVATION OF IKKS COMPLEX
11.3.4.6.1.2 MAP KINASE ACTIVATION
11.3.4.6.1.2.1 MAPK TARGETS/ NUCLEAR EVENTS MEDIATED BY MAP KINASES
11.3.4.6.1.2.1.1 ERK/MAPK TARGETS
11.3.4.6.1.2.1.1.1 ERKS ARE INACTIVATED
11.3.4.6.1.2.1.2 CREB PHOSPHORYLATION
11.3.4.6.1.2.1.3 ACTIVATION OF THE AP-1 FAMILY OF TRANSCRIPTION FACTORS
11.3.4.6.1.2.2 ACTIVATED TAK1 MEDIATES P38 MAPK ACTIVATION
11.3.4.6.1.2.3 JNK (C-JUN KINASES) PHOSPHORYLATION AND  ACTIVATION MEDIATED BY ACTIVATED HUMAN TAK1
11.3.4.6.1.2.4 MAP3K8 (TPL2)-DEPENDENT MAPK1/3 ACTIVATION
11.3.4.6.1.3 IRAK1 RECRUITS IKK COMPLEX
11.3.4.6.1.4 IRAK2 MEDIATED ACTIVATION OF TAK1 COMPLEX
11.3.4.7 TOLL LIKE RECEPTOR 7/8 (TLR7/8) CASCADE
11.3.4.7.1 MYD88 DEPENDENT CASCADE INITIATED ON ENDOSOME
11.3.4.7.1.1 TRAF6 MEDIATED IRF7 ACTIVATION IN TLR7/8 OR 9 SIGNALING
11.3.4.7.1.2 TRAF6 MEDIATED INDUCTION OF NFKB AND MAP KINASES UPON TLR7/8 OR 9 ACTIVATION
11.3.4.7.1.2.1 TAK1 ACTIVATES NFKB BY PHOSPHORYLATION AND ACTIVATION OF IKKS COMPLEX
11.3.4.7.1.2.2 MAP KINASE ACTIVATION
11.3.4.7.1.2.2.1 MAPK TARGETS/ NUCLEAR EVENTS MEDIATED BY MAP KINASES
11.3.4.7.1.2.2.1.1 ERK/MAPK TARGETS
11.3.4.7.1.2.2.1.1.1 ERKS ARE INACTIVATED
11.3.4.7.1.2.2.1.2 CREB PHOSPHORYLATION
11.3.4.7.1.2.2.1.3 ACTIVATION OF THE AP-1 FAMILY OF TRANSCRIPTION FACTORS
11.3.4.7.1.2.2.2 ACTIVATED TAK1 MEDIATES P38 MAPK ACTIVATION
11.3.4.7.1.2.2.3 JNK (C-JUN KINASES) PHOSPHORYLATION AND  ACTIVATION MEDIATED BY ACTIVATED HUMAN TAK1
11.3.4.7.1.2.2.4 MAP3K8 (TPL2)-DEPENDENT MAPK1/3 ACTIVATION
11.3.4.7.1.2.3 IRAK1 RECRUITS IKK COMPLEX UPON TLR7/8 OR 9 STIMULATION
11.3.4.7.1.2.4 IRAK2 MEDIATED ACTIVATION OF TAK1 COMPLEX UPON TLR7/8 OR 9 STIMULATION
11.3.4.8 TOLL LIKE RECEPTOR 2 (TLR2) CASCADE
11.3.4.8.1 TOLL LIKE RECEPTOR TLR1:TLR2 CASCADE
11.3.4.8.1.1 MYD88:MAL(TIRAP) CASCADE INITIATED ON PLASMA MEMBRANE
11.3.4.8.1.1.1 TAK1 ACTIVATES NFKB BY PHOSPHORYLATION AND ACTIVATION OF IKKS COMPLEX
11.3.4.8.1.1.2 MAP KINASE ACTIVATION
11.3.4.8.1.1.2.1 MAPK TARGETS/ NUCLEAR EVENTS MEDIATED BY MAP KINASES
11.3.4.8.1.1.2.1.1 ERK/MAPK TARGETS
11.3.4.8.1.1.2.1.1.1 ERKS ARE INACTIVATED
11.3.4.8.1.1.2.1.2 CREB PHOSPHORYLATION
11.3.4.8.1.1.2.1.3 ACTIVATION OF THE AP-1 FAMILY OF TRANSCRIPTION FACTORS
11.3.4.8.1.1.2.2 ACTIVATED TAK1 MEDIATES P38 MAPK ACTIVATION
11.3.4.8.1.1.2.3 JNK (C-JUN KINASES) PHOSPHORYLATION AND  ACTIVATION MEDIATED BY ACTIVATED HUMAN TAK1
11.3.4.8.1.1.2.4 MAP3K8 (TPL2)-DEPENDENT MAPK1/3 ACTIVATION
11.3.4.8.1.1.3 IRAK1 RECRUITS IKK COMPLEX
11.3.4.8.1.1.4 IRAK2 MEDIATED ACTIVATION OF TAK1 COMPLEX
11.3.4.8.2 TOLL LIKE RECEPTOR TLR6:TLR2 CASCADE
11.3.4.8.2.1 MYD88:MAL(TIRAP) CASCADE INITIATED ON PLASMA MEMBRANE
11.3.4.8.2.1.1 TAK1 ACTIVATES NFKB BY PHOSPHORYLATION AND ACTIVATION OF IKKS COMPLEX
11.3.4.8.2.1.2 MAP KINASE ACTIVATION
11.3.4.8.2.1.2.1 MAPK TARGETS/ NUCLEAR EVENTS MEDIATED BY MAP KINASES
11.3.4.8.2.1.2.1.1 ERK/MAPK TARGETS
11.3.4.8.2.1.2.1.1.1 ERKS ARE INACTIVATED
11.3.4.8.2.1.2.1.2 CREB PHOSPHORYLATION
11.3.4.8.2.1.2.1.3 ACTIVATION OF THE AP-1 FAMILY OF TRANSCRIPTION FACTORS
11.3.4.8.2.1.2.2 ACTIVATED TAK1 MEDIATES P38 MAPK ACTIVATION
11.3.4.8.2.1.2.3 JNK (C-JUN KINASES) PHOSPHORYLATION AND  ACTIVATION MEDIATED BY ACTIVATED HUMAN TAK1
11.3.4.8.2.1.2.4 MAP3K8 (TPL2)-DEPENDENT MAPK1/3 ACTIVATION
11.3.4.8.2.1.3 IRAK1 RECRUITS IKK COMPLEX
11.3.4.8.2.1.4 IRAK2 MEDIATED ACTIVATION OF TAK1 COMPLEX
11.3.4.9 REGULATION OF TLR BY ENDOGENOUS LIGAND
11.3.5 DDX58/IFIH1-MEDIATED INDUCTION OF INTERFERON-ALPHA/BETA
11.3.5.1 TRAF3-DEPENDENT IRF ACTIVATION PATHWAY
11.3.5.2 TRAF6 MEDIATED IRF7 ACTIVATION
11.3.5.3 TRAF6 MEDIATED NF-KB ACTIVATION
11.3.5.4 NF-KB ACTIVATION THROUGH FADD/RIP-1 PATHWAY MEDIATED BY CASPASE-8 AND -10
11.3.5.5 NEGATIVE REGULATORS OF DDX58/IFIH1 SIGNALING
11.3.6 CYTOSOLIC SENSORS OF PATHOGEN-ASSOCIATED DNA
11.3.6.1 ZBP1(DAI) MEDIATED INDUCTION OF TYPE I IFNS
11.3.6.1.1 IRF3 MEDIATED ACTIVATION OF TYPE 1 IFN
11.3.6.1.2 RIP-MEDIATED NFKB ACTIVATION VIA ZBP1
11.3.6.2 STING MEDIATED INDUCTION OF HOST IMMUNE RESPONSES
11.3.6.2.1 STAT6-MEDIATED INDUCTION OF CHEMOKINES
11.3.6.2.2 IRF3-MEDIATED INDUCTION OF TYPE I IFN
11.3.6.3 DEX/H-BOX HELICASES ACTIVATE TYPE I IFN AND INFLAMMATORY CYTOKINES PRODUCTION
11.3.6.4 LRR FLII-INTERACTING PROTEIN 1 (LRRFIP1) ACTIVATES TYPE I IFN PRODUCTION
11.3.6.5 REGULATION OF INNATE IMMUNE RESPONSES TO CYTOSOLIC DNA
11.3.6.5.1 REGULATION BY TREX1
11.3.7 FCGAMMA RECEPTOR (FCGR) DEPENDENT PHAGOCYTOSIS
11.3.7.1 FCGR ACTIVATION
11.3.7.2 REGULATION OF ACTIN DYNAMICS FOR PHAGOCYTIC CUP FORMATION
11.3.7.3 ROLE OF PHOSPHOLIPIDS IN PHAGOCYTOSIS
11.3.8 DAP12 INTERACTIONS
11.3.8.1 DAP12 SIGNALING
11.3.9 FC EPSILON RECEPTOR (FCERI) SIGNALING
11.3.9.1 ROLE OF LAT2/NTAL/LAB ON CALCIUM MOBILIZATION
11.3.9.2 FCERI MEDIATED MAPK ACTIVATION
11.3.9.3 FCERI MEDIATED CA+2 MOBILIZATION
11.3.9.4 FCERI MEDIATED NF-KB ACTIVATION
11.3.10 C-TYPE LECTIN RECEPTORS (CLRS)
11.3.10.1 CLEC7A (DECTIN-1) SIGNALING
11.3.10.1.1 DECTIN-1 MEDIATED NONCANONICAL NF-KB SIGNALING
11.3.10.1.2 CLEC7A (DECTIN-1) INDUCES NFAT ACTIVATION
11.3.10.1.3 CLEC7A/INFLAMMASOME PATHWAY
11.3.10.2 DECTIN-2 FAMILY
11.3.10.3 CD209 (DC-SIGN) SIGNALING
11.3.11 NEUTROPHIL DEGRANULATION
11.3.12 ANTIMICROBIAL PEPTIDES
11.3.12.1 DEFENSINS
11.3.12.1.1 BETA DEFENSINS
11.3.12.1.2 ALPHA-DEFENSINS
11.3.12.2 METAL SEQUESTRATION BY ANTIMICROBIAL PROTEINS
11.3.12.3 ION INFLUX/EFFLUX AT HOST-PATHOGEN INTERFACE
11.3.13 ADVANCED GLYCOSYLATION ENDPRODUCT RECEPTOR SIGNALING
12 ORGANELLE BIOGENESIS AND MAINTENANCE
12.1 MITOCHONDRIAL BIOGENESIS
12.1.1 TRANSCRIPTIONAL ACTIVATION OF MITOCHONDRIAL BIOGENESIS
12.1.2 ACTIVATION OF PPARGC1A (PGC-1ALPHA) BY PHOSPHORYLATION
12.1.3 CRISTAE FORMATION
12.2 CILIUM ASSEMBLY
12.2.1 ANCHORING OF THE BASAL BODY TO THE PLASMA MEMBRANE
12.2.2 CARGO TRAFFICKING TO THE PERICILIARY MEMBRANE
12.2.2.1 VXPX CARGO-TARGETING TO CILIUM
12.2.2.2 BBSOME-MEDIATED CARGO-TARGETING TO CILIUM
12.2.2.3 TRAFFICKING OF MYRISTOYLATED PROTEINS TO THE CILIUM
12.2.2.4 ARL13B-MEDIATED CILIARY TRAFFICKING OF INPP5E
12.2.3 INTRAFLAGELLAR TRANSPORT
13 TRANSPORT OF SMALL MOLECULES
13.1 O2/CO2 EXCHANGE IN ERYTHROCYTES
13.1.1 ERYTHROCYTES TAKE UP CARBON DIOXIDE AND RELEASE OXYGEN
13.1.2 ERYTHROCYTES TAKE UP OXYGEN AND RELEASE CARBON DIOXIDE
13.2 "PLASMA LIPOPROTEIN ASSEMBLY, REMODELING, AND CLEARANCE"
13.2.1 PLASMA LIPOPROTEIN ASSEMBLY
13.2.1.1 VLDL ASSEMBLY
13.2.1.2 CHYLOMICRON ASSEMBLY
13.2.1.3 HDL ASSEMBLY
13.2.2 PLASMA LIPOPROTEIN REMODELING
13.2.2.1 ASSEMBLY OF ACTIVE LPL AND LIPC LIPASE COMPLEXES
13.2.2.2 CHYLOMICRON REMODELING
13.2.2.3 LDL REMODELING
13.2.2.4 HDL REMODELING
13.2.3 PLASMA LIPOPROTEIN CLEARANCE
13.2.3.1 VLDLR INTERNALISATION AND DEGRADATION
13.2.3.2 HDL CLEARANCE
13.2.3.3 CHYLOMICRON CLEARANCE
13.2.3.4 LDL CLEARANCE
13.2.3.5 VLDL CLEARANCE
13.3 ABC-FAMILY PROTEINS MEDIATED TRANSPORT
13.3.1 MITOCHONDRIAL ABC TRANSPORTERS
13.3.2 ABC TRANSPORTERS IN LIPID HOMEOSTASIS
13.4 SLC-MEDIATED TRANSMEMBRANE TRANSPORT
13.4.1 CELLULAR HEXOSE TRANSPORT
13.4.2 "TRANSPORT OF BILE SALTS AND ORGANIC ACIDS, METAL IONS AND AMINE COMPOUNDS"
13.4.2.1 METAL ION SLC TRANSPORTERS
13.4.2.1.1 ZINC TRANSPORTERS
13.4.2.1.1.1 ZINC EFFLUX AND COMPARTMENTALIZATION BY THE SLC30 FAMILY
13.4.2.1.1.2 ZINC INFLUX INTO CELLS BY THE SLC39 GENE FAMILY
13.4.2.2 INOSITOL TRANSPORTERS
13.4.2.3 "SODIUM-COUPLED SULPHATE, DI- AND TRI-CARBOXYLATE TRANSPORTERS"
13.4.2.4 PROTON-COUPLED MONOCARBOXYLATE TRANSPORT
13.4.2.5 NA+/CL- DEPENDENT NEUROTRANSMITTER TRANSPORTERS
13.4.2.6 RHESUS GLYCOPROTEINS MEDIATE AMMONIUM TRANSPORT.
13.4.2.7 ORGANIC CATION/ANION/ZWITTERION TRANSPORT
13.4.2.7.1 ORGANIC CATION TRANSPORT
13.4.2.7.2 ORGANIC ANION TRANSPORT
13.4.3 TRANSPORT OF INORGANIC CATIONS/ANIONS AND AMINO ACIDS/OLIGOPEPTIDES
13.4.3.1 AMINO ACID TRANSPORT ACROSS THE PLASMA MEMBRANE
13.4.3.2 BICARBONATE TRANSPORTERS
13.4.3.3 SODIUM/CALCIUM EXCHANGERS
13.4.3.4 SODIUM/PROTON EXCHANGERS
13.4.3.5 CATION-COUPLED CHLORIDE COTRANSPORTERS
13.4.3.6 MULTIFUNCTIONAL ANION EXCHANGERS
13.4.3.7 SODIUM-COUPLED PHOSPHATE COTRANSPORTERS
13.4.3.7.1 TYPE II NA+/PI COTRANSPORTERS
13.4.3.8 PROTON/OLIGOPEPTIDE COTRANSPORTERS
13.4.3.9 PROTON-COUPLED NEUTRAL AMINO ACID TRANSPORTERS
13.4.3.10 ORGANIC ANION TRANSPORTERS
13.4.4 "TRANSPORT OF VITAMINS, NUCLEOSIDES, AND RELATED MOLECULES"
13.4.4.1 TRANSPORT OF NUCLEOTIDE SUGARS
13.4.4.2 TRANSPORT OF FATTY ACIDS
13.4.4.3 TRANSPORT OF NUCLEOSIDES AND FREE PURINE AND PYRIMIDINE BASES ACROSS THE PLASMA MEMBRANE
13.4.4.4 TRANSPORT OF ORGANIC ANIONS
13.5 AQUAPORIN-MEDIATED TRANSPORT
13.5.1 TRANSPORT OF GLYCEROL FROM ADIPOCYTES TO THE LIVER BY AQUAPORINS
13.5.2 VASOPRESSIN REGULATES RENAL WATER HOMEOSTASIS VIA AQUAPORINS
13.5.3 PASSIVE TRANSPORT BY AQUAPORINS
13.6 MISCELLANEOUS TRANSPORT AND BINDING EVENTS
13.7 MITOCHONDRIAL CALCIUM ION TRANSPORT
13.7.1 PROCESSING OF SMDT1
13.8 INTRACELLULAR OXYGEN TRANSPORT
13.9 IRON UPTAKE AND TRANSPORT
13.9.1 TRANSFERRIN ENDOCYTOSIS AND RECYCLING
13.1 ION CHANNEL TRANSPORT
13.10.1 STIMULI-SENSING CHANNELS
13.10.1.1 TRP CHANNELS
13.10.2 ION TRANSPORT BY P-TYPE ATPASES
14 METABOLISM OF PROTEINS
14.1 PEPTIDE HORMONE METABOLISM
14.1.1 METABOLISM OF ANGIOTENSINOGEN TO ANGIOTENSINS
14.1.2 PEPTIDE HORMONE BIOSYNTHESIS
14.1.2.1 GLYCOPROTEIN HORMONES
14.1.3 INSULIN PROCESSING
14.1.4 "INCRETIN SYNTHESIS, SECRETION, AND INACTIVATION"
14.1.4.1 "SYNTHESIS, SECRETION, AND INACTIVATION OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1)"
14.1.4.2 "SYNTHESIS, SECRETION, AND INACTIVATION OF GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE (GIP)"
14.1.5 "SYNTHESIS, SECRETION, AND DEACYLATION OF GHRELIN"
14.2 UNFOLDED PROTEIN RESPONSE (UPR)
14.2.1 ATF6 (ATF6-ALPHA) ACTIVATES CHAPERONES
14.2.1.1 ATF6 (ATF6-ALPHA) ACTIVATES CHAPERONE GENES
14.2.2 PERK REGULATES GENE EXPRESSION
14.2.2.1 ATF4 ACTIVATES GENES
14.2.3 IRE1ALPHA ACTIVATES CHAPERONES
14.2.3.1 XBP1(S) ACTIVATES CHAPERONE GENES
14.2.4 CREB3 FACTORS ACTIVATE GENES
14.3 REGULATION OF INSULIN-LIKE GROWTH FACTOR (IGF) TRANSPORT AND UPTAKE BY INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS (IGFBPS)
14.4 PROTEIN FOLDING
14.4.1 POST-CHAPERONIN TUBULIN FOLDING PATHWAY
14.4.2 CHAPERONIN-MEDIATED PROTEIN FOLDING
14.4.2.1 COOPERATION OF PREFOLDIN AND TRIC/CCT  IN ACTIN AND TUBULIN FOLDING
14.4.2.1.1 PREFOLDIN MEDIATED TRANSFER OF SUBSTRATE  TO CCT/TRIC
14.4.2.1.2 FORMATION OF TUBULIN FOLDING INTERMEDIATES BY CCT/TRIC
14.4.2.1.3 FOLDING OF ACTIN BY CCT/TRIC
14.4.2.2 ASSOCIATION OF TRIC/CCT WITH TARGET PROTEINS DURING BIOSYNTHESIS
14.4.2.3 COOPERATION OF PDCL (PHLP1) AND TRIC/CCT IN G-PROTEIN BETA FOLDING
14.5 PROTEIN REPAIR
14.6 SURFACTANT METABOLISM
14.7 POST-TRANSLATIONAL PROTEIN MODIFICATION
14.7.1 POST-TRANSLATIONAL MODIFICATION: SYNTHESIS OF GPI-ANCHORED PROTEINS
14.7.1.1 SYNTHESIS OF DOLICHYL-PHOSPHATE MANNOSE
14.7.1.2 SYNTHESIS OF GLYCOSYLPHOSPHATIDYLINOSITOL (GPI)
14.7.1.3 ATTACHMENT OF GPI ANCHOR TO UPAR
14.7.2 "GAMMA CARBOXYLATION, HYPUSINE FORMATION AND ARYLSULFATASE ACTIVATION"
14.7.2.1 "GAMMA-CARBOXYLATION, TRANSPORT, AND AMINO-TERMINAL CLEAVAGE OF PROTEINS"
14.7.2.1.1 GAMMA-CARBOXYLATION OF PROTEIN PRECURSORS
14.7.2.1.2 TRANSPORT OF GAMMA-CARBOXYLATED PROTEIN PRECURSORS FROM THE ENDOPLASMIC RETICULUM TO THE GOLGI APPARATUS
14.7.2.1.3 REMOVAL OF AMINOTERMINAL PROPEPTIDES FROM GAMMA-CARBOXYLATED PROTEINS
14.7.2.2 THE ACTIVATION OF ARYLSULFATASES
14.7.2.3 HYPUSINE SYNTHESIS FROM EIF5A-LYSINE
14.7.2.4 SYNTHESIS OF DIPHTHAMIDE-EEF2
14.7.3 SUMOYLATION
14.7.3.1 SUMO E3 LIGASES SUMOYLATE TARGET PROTEINS
14.7.3.1.1 SUMOYLATION OF DNA DAMAGE RESPONSE AND REPAIR PROTEINS
14.7.3.1.2 SUMOYLATION OF TRANSCRIPTION FACTORS
14.7.3.1.3 SUMOYLATION OF UBIQUITINYLATION PROTEINS
14.7.3.1.4 SUMOYLATION OF TRANSCRIPTION COFACTORS
14.7.3.1.5 SUMOYLATION OF SUMOYLATION PROTEINS
14.7.3.1.6 SUMOYLATION OF INTRACELLULAR RECEPTORS
14.7.3.1.7 SUMOYLATION OF CHROMATIN ORGANIZATION PROTEINS
14.7.3.1.8 SUMOYLATION OF RNA BINDING PROTEINS
14.7.3.1.9 SUMOYLATION OF DNA REPLICATION PROTEINS
14.7.3.1.10 SUMOYLATION OF DNA METHYLATION PROTEINS
14.7.3.1.11 SUMOYLATION OF IMMUNE RESPONSE PROTEINS
14.7.3.2 PROCESSING AND ACTIVATION OF SUMO
14.7.3.2.1 SUMO IS CONJUGATED TO E1 (UBA2:SAE1)
14.7.3.2.2 "SUMO IS TRANSFERRED FROM E1 TO E2 (UBE2I, UBC9)"
14.7.3.2.3 SUMO IS PROTEOLYTICALLY PROCESSED
14.7.4 ASPARAGINE N-LINKED GLYCOSYLATION
14.7.4.1 "BIOSYNTHESIS OF THE N-GLYCAN PRECURSOR (DOLICHOL LIPID-LINKED OLIGOSACCHARIDE, LLO) AND TRANSFER TO A NASCENT PROTEIN"
14.7.4.1.1 SYNTHESIS OF SUBSTRATES IN N-GLYCAN BIOSYTHESIS
14.7.4.1.1.1 SYNTHESIS OF DOLICHYL-PHOSPHATE MANNOSE
14.7.4.1.1.2 SIALIC ACID METABOLISM
14.7.4.1.1.3 SYNTHESIS OF DOLICHYL-PHOSPHATE
14.7.4.1.1.4 SYNTHESIS OF GDP-MANNOSE
14.7.4.1.1.5 SYNTHESIS OF UDP-N-ACETYL-GLUCOSAMINE
14.7.4.1.1.6 SYNTHESIS OF DOLICHYL-PHOSPHATE-GLUCOSE
14.7.4.1.1.7 GDP-FUCOSE BIOSYNTHESIS
14.7.4.2 N-GLYCAN TRIMMING IN THE ER AND CALNEXIN/CALRETICULIN CYCLE
14.7.4.2.1 CALNEXIN/CALRETICULIN CYCLE
14.7.4.2.1.1 ER QUALITY CONTROL COMPARTMENT (ERQC)
14.7.4.3 TRANSPORT TO THE GOLGI AND SUBSEQUENT MODIFICATION
14.7.4.3.1 ER TO GOLGI ANTEROGRADE TRANSPORT
14.7.4.3.1.1 COPII-MEDIATED VESICLE TRANSPORT
14.7.4.3.1.2 CARGO CONCENTRATION IN THE ER
14.7.4.3.1.3 COPI-MEDIATED ANTEROGRADE TRANSPORT
14.7.4.3.2 N-GLYCAN TRIMMING AND ELONGATION IN THE CIS-GOLGI
14.7.4.3.2.1 "PROGRESSIVE TRIMMING OF ALPHA-1,2-LINKED MANNOSE RESIDUES FROM MAN9/8/7GLCNAC2 TO PRODUCE MAN5GLCNAC2"
14.7.4.3.3 N-GLYCAN ANTENNAE ELONGATION IN THE MEDIAL/TRANS-GOLGI
14.7.4.3.3.1 REACTIONS SPECIFIC TO THE HYBRID N-GLYCAN SYNTHESIS PATHWAY
14.7.4.3.3.2 N-GLYCAN ANTENNAE ELONGATION
14.7.4.3.3.3 REACTIONS SPECIFIC TO THE COMPLEX N-GLYCAN SYNTHESIS PATHWAY
14.7.5 O-LINKED GLYCOSYLATION
14.7.5.1 O-GLYCOSYLATION OF TSR DOMAIN-CONTAINING PROTEINS
14.7.5.2 O-LINKED GLYCOSYLATION OF MUCINS
14.7.5.2.1 TERMINATION OF O-GLYCAN BIOSYNTHESIS
14.7.6 DEUBIQUITINATION
14.7.6.1 UCH PROTEINASES
14.7.6.2 JOSEPHIN DOMAIN DUBS
14.7.6.3 UB-SPECIFIC PROCESSING PROTEASES
14.7.6.4 OVARIAN TUMOR DOMAIN PROTEASES
14.7.6.5 METALLOPROTEASE DUBS
14.7.7 PROTEIN UBIQUITINATION
14.7.7.1 SYNTHESIS OF ACTIVE UBIQUITIN: ROLES OF E1 AND E2 ENZYMES
14.7.7.2 E3 UBIQUITIN LIGASES UBIQUITINATE TARGET PROTEINS
14.7.8 RAB GERANYLGERANYLATION
14.7.9 PROTEIN METHYLATION
14.7.10 NEDDYLATION
14.7.11 CARBOXYTERMINAL POST-TRANSLATIONAL MODIFICATIONS OF TUBULIN
14.7.12 POST-TRANSLATIONAL PROTEIN PHOSPHORYLATION
14.8 TRANSLATION
14.8.1 EUKARYOTIC TRANSLATION ELONGATION
14.8.1.1 PEPTIDE CHAIN ELONGATION
14.8.2 SRP-DEPENDENT COTRANSLATIONAL PROTEIN TARGETING TO MEMBRANE
14.8.3 TRNA AMINOACYLATION
14.8.3.1 CYTOSOLIC TRNA AMINOACYLATION
14.8.3.2 MITOCHONDRIAL TRNA AMINOACYLATION
14.8.4 MITOCHONDRIAL TRANSLATION
14.8.4.1 MITOCHONDRIAL TRANSLATION INITIATION
14.8.4.2 MITOCHONDRIAL TRANSLATION ELONGATION
14.8.4.3 MITOCHONDRIAL TRANSLATION TERMINATION
14.8.5 EUKARYOTIC TRANSLATION INITIATION
14.8.5.1 L13A-MEDIATED TRANSLATIONAL SILENCING OF CERULOPLASMIN EXPRESSION
14.8.5.2 CAP-DEPENDENT TRANSLATION INITIATION
14.8.5.2.1 "ACTIVATION OF THE MRNA UPON BINDING OF THE CAP-BINDING COMPLEX AND EIFS, AND SUBSEQUENT BINDING TO 43S"
14.8.5.2.1.1 TRANSLATION INITIATION COMPLEX FORMATION
14.8.5.2.2 FORMATION OF A POOL OF FREE 40S SUBUNITS
14.8.5.2.3 "FORMATION OF THE TERNARY COMPLEX, AND SUBSEQUENTLY, THE 43S COMPLEX"
14.8.5.2.4 RIBOSOMAL SCANNING AND START CODON RECOGNITION
14.8.5.2.5 GTP HYDROLYSIS AND JOINING OF THE 60S RIBOSOMAL SUBUNIT
14.8.5.2.6 RECYCLING OF EIF2:GDP
14.8.6 EUKARYOTIC TRANSLATION TERMINATION
14.9 AMYLOID FIBER FORMATION
15 MUSCLE CONTRACTION
15.1 STRIATED MUSCLE CONTRACTION
15.2 SMOOTH MUSCLE CONTRACTION
15.3 CARDIAC CONDUCTION
15.3.1 PHASE 4 - RESTING MEMBRANE POTENTIAL
15.3.2 PHASE 3 - RAPID REPOLARISATION
15.3.3 PHASE 0 - RAPID DEPOLARISATION
15.3.4 PHASE 2 - PLATEAU PHASE
15.3.5 PHASE 1 - INACTIVATION OF FAST NA+ CHANNELS
15.3.6 PHYSIOLOGICAL FACTORS
15.3.7 ION HOMEOSTASIS
16 CIRCADIAN CLOCK
16.1 NR1D1 (REV-ERBA) REPRESSES GENE EXPRESSION
16.2 RORA ACTIVATES GENE EXPRESSION
16.3 "BMAL1:CLOCK,NPAS2 ACTIVATES CIRCADIAN GENE EXPRESSION"
17 CHROMATIN ORGANIZATION
17.1 CHROMATIN MODIFYING ENZYMES
17.1.1 HDACS DEACETYLATE HISTONES
17.1.2 PKMTS METHYLATE HISTONE LYSINES
17.1.3 HDMS DEMETHYLATE HISTONES
17.1.4 HATS ACETYLATE HISTONES
17.1.5 RMTS METHYLATE HISTONE ARGININES
18 MITOPHAGY
18.1 PINK/PARKIN MEDIATED MITOPHAGY
18.2 RECEPTOR MEDIATED MITOPHAGY
19 PROGRAMMED CELL DEATH
19.1 APOPTOSIS
19.1.1 INTRINSIC PATHWAY FOR APOPTOSIS
19.1.1.1 ACTIVATION AND OLIGOMERIZATION OF BAK PROTEIN
19.1.1.2 BH3-ONLY PROTEINS ASSOCIATE WITH AND INACTIVATE ANTI-APOPTOTIC BCL-2 MEMBERS
19.1.1.3 APOPTOTIC FACTOR-MEDIATED RESPONSE
19.1.1.3.1 RELEASE OF APOPTOTIC FACTORS FROM THE MITOCHONDRIA
19.1.1.3.2 CYTOCHROME C-MEDIATED APOPTOTIC RESPONSE
19.1.1.3.2.1 FORMATION OF APOPTOSOME
19.1.1.3.2.1.1 REGULATION OF THE APOPTOSOME ACTIVITY
19.1.1.3.2.2 ACTIVATION OF CASPASES THROUGH APOPTOSOME-MEDIATED CLEAVAGE
19.1.1.3.3 "SMAC, XIAP-REGULATED APOPTOTIC RESPONSE"
19.1.1.3.3.1 SMAC (DIABLO) BINDS TO IAPS
19.1.1.3.3.2 SMAC(DIABLO)-MEDIATED DISSOCIATION OF IAP:CASPASE COMPLEXES
19.1.1.4 "ACTIVATION, TRANSLOCATION AND OLIGOMERIZATION OF BAX"
19.1.1.5 ACTIVATION OF BH3-ONLY PROTEINS
19.1.1.5.1 ACTIVATION OF BIM AND TRANSLOCATION TO MITOCHONDRIA
19.1.1.5.2 ACTIVATION OF BAD AND TRANSLOCATION TO MITOCHONDRIA
19.1.1.5.3 ACTIVATION OF NOXA AND TRANSLOCATION TO MITOCHONDRIA
19.1.1.5.4 ACTIVATION OF BMF AND TRANSLOCATION TO MITOCHONDRIA
19.1.1.5.5 ACTIVATION OF PUMA AND TRANSLOCATION TO MITOCHONDRIA
19.1.1.6 "ACTIVATION, MYRISTOLYATION OF BID AND TRANSLOCATION TO MITOCHONDRIA"
19.1.2 REGULATION OF APOPTOSIS
19.1.2.1 REGULATION OF PAK-2P34 ACTIVITY BY PS-GAP/RHG10
19.1.2.2 REGULATION OF ACTIVATED PAK-2P34 BY PROTEASOME MEDIATED DEGRADATION
19.1.3 CASPASE ACTIVATION VIA EXTRINSIC APOPTOTIC SIGNALLING PATHWAY
19.1.3.1 CASPASE ACTIVATION VIA DEATH RECEPTORS IN THE PRESENCE OF LIGAND
19.1.3.1.1 REGULATION BY C-FLIP
19.1.3.1.2 DIMERIZATION OF PROCASPASE-8
19.1.3.2 CASPASE ACTIVATION VIA DEPENDENCE RECEPTORS IN THE ABSENCE OF LIGAND
19.1.4 APOPTOTIC EXECUTION PHASE
19.1.4.1 APOPTOTIC CLEAVAGE OF CELLULAR PROTEINS
19.1.4.1.1 CASPASE-MEDIATED CLEAVAGE OF CYTOSKELETAL PROTEINS
19.1.4.1.2 APOPTOTIC CLEAVAGE OF CELL ADHESION  PROTEINS
19.1.4.1.3 BREAKDOWN OF THE NUCLEAR LAMINA
19.1.4.2 APOPTOSIS INDUCED DNA FRAGMENTATION
19.1.4.2.1 ACTIVATION OF DNA FRAGMENTATION FACTOR
19.1.4.3 STIMULATION OF THE CELL DEATH RESPONSE BY PAK-2P34
19.2 REGULATED NECROSIS
19.2.1 RIPK1-MEDIATED REGULATED NECROSIS
19.2.1.1 REGULATION OF NECROPTOTIC CELL DEATH
19.2.1.1.1 CASP8 ACTIVITY IS INHIBITED
20 VESICLE-MEDIATED TRANSPORT
20.1 MEMBRANE TRAFFICKING
20.1.1 TRANSLOCATION OF SLC2A4 (GLUT4) TO THE PLASMA MEMBRANE
20.1.2 GAP JUNCTION TRAFFICKING AND REGULATION
20.1.2.1 GAP JUNCTION TRAFFICKING
20.1.2.1.1 GAP JUNCTION ASSEMBLY
20.1.2.1.1.1 OLIGOMERIZATION OF CONNEXINS INTO CONNEXONS
20.1.2.1.1.2 TRANSPORT OF CONNEXINS ALONG THE SECRETORY PATHWAY
20.1.2.1.1.3 TRANSPORT OF CONNEXONS TO THE PLASMA MEMBRANE
20.1.2.1.1.3.1 MICROTUBULE-DEPENDENT TRAFFICKING OF CONNEXONS FROM GOLGI TO THE PLASMA MEMBRANE
20.1.2.1.2 GAP JUNCTION DEGRADATION
20.1.2.1.2.1 FORMATION OF ANNULAR GAP JUNCTIONS
20.1.2.2 REGULATION OF GAP JUNCTION ACTIVITY
20.1.2.2.1 C-SRC MEDIATED REGULATION OF CX43 FUNCTION AND CLOSURE OF GAP JUNCTIONS
20.1.3 ER TO GOLGI ANTEROGRADE TRANSPORT
20.1.3.1 COPII-MEDIATED VESICLE TRANSPORT
20.1.3.2 CARGO CONCENTRATION IN THE ER
20.1.3.3 COPI-MEDIATED ANTEROGRADE TRANSPORT
20.1.4 TRANS-GOLGI NETWORK VESICLE BUDDING
20.1.4.1 CLATHRIN DERIVED VESICLE BUDDING
20.1.4.1.1 LYSOSOME VESICLE BIOGENESIS
20.1.4.1.2 GOLGI ASSOCIATED VESICLE BIOGENESIS
20.1.5 INTRA-GOLGI AND RETROGRADE GOLGI-TO-ER TRAFFIC
20.1.5.1 INTRA-GOLGI TRAFFIC
20.1.5.2 RETROGRADE TRANSPORT AT THE TRANS-GOLGI-NETWORK
20.1.5.3 GOLGI-TO-ER RETROGRADE TRANSPORT
20.1.5.3.1 COPI-DEPENDENT GOLGI-TO-ER RETROGRADE TRAFFIC
20.1.5.3.2 COPI-INDEPENDENT GOLGI-TO-ER RETROGRADE TRAFFIC
20.1.6 CLATHRIN-MEDIATED ENDOCYTOSIS
20.1.6.1 CARGO RECOGNITION FOR CLATHRIN-MEDIATED ENDOCYTOSIS
20.1.7 RAB REGULATION OF TRAFFICKING
20.1.7.1 TBC/RABGAPS
20.1.7.2 RAB GEFS EXCHANGE GTP FOR GDP ON RABS
20.1.8 ENDOSOMAL SORTING COMPLEX REQUIRED FOR TRANSPORT (ESCRT)
20.2 BINDING AND UPTAKE OF LIGANDS BY SCAVENGER RECEPTORS
20.2.1 SCAVENGING OF HEME FROM PLASMA
20.2.2 SCAVENGING BY CLASS B RECEPTORS
20.2.3 SCAVENGING BY CLASS A RECEPTORS
20.2.4 SCAVENGING BY CLASS F RECEPTORS
20.2.5 SCAVENGING BY CLASS H RECEPTORS
21 DNA REPLICATION
21.1 DNA REPLICATION PRE-INITIATION
21.1.1 ASSEMBLY OF THE PRE-REPLICATIVE COMPLEX
21.1.1.1 ASSEMBLY OF THE ORC COMPLEX AT THE ORIGIN OF REPLICATION
21.1.1.2 CDC6 ASSOCIATION WITH THE ORC:ORIGIN COMPLEX
21.1.1.3 CDT1 ASSOCIATION WITH THE CDC6:ORC:ORIGIN COMPLEX
21.1.2 ACTIVATION OF THE PRE-REPLICATIVE COMPLEX
21.2 SYNTHESIS OF DNA
21.2.1 DNA REPLICATION INITIATION
21.2.2 SWITCHING OF ORIGINS TO A POST-REPLICATIVE STATE
21.2.2.1 ORC1 REMOVAL FROM CHROMATIN
21.2.2.2 CDK-MEDIATED PHOSPHORYLATION AND REMOVAL OF CDC6
21.2.3 DNA STRAND ELONGATION
21.2.3.1 UNWINDING OF DNA
21.2.3.2 LEADING STRAND SYNTHESIS
21.2.3.2.1 POLYMERASE SWITCHING
21.2.3.3 LAGGING STRAND SYNTHESIS
21.2.3.3.1 POLYMERASE SWITCHING
21.2.3.3.2 PROCESSIVE SYNTHESIS ON THE LAGGING STRAND
21.2.3.3.2.1 REMOVAL OF THE FLAP INTERMEDIATE
22 DNA REPAIR
22.1 MISMATCH REPAIR
22.1.1 MISMATCH REPAIR (MMR) DIRECTED BY MSH2:MSH6 (MUTSALPHA)
22.1.2 MISMATCH REPAIR (MMR) DIRECTED BY MSH2:MSH3 (MUTSBETA)
22.2 DNA DOUBLE-STRAND BREAK REPAIR
22.2.1 HOMOLOGY DIRECTED REPAIR
22.2.1.1 HDR THROUGH MMEJ (ALT-NHEJ)
22.2.1.2 HDR THROUGH HOMOLOGOUS RECOMBINATION (HRR) OR SINGLE STRAND ANNEALING (SSA)
22.2.1.2.1 HDR THROUGH SINGLE STRAND ANNEALING (SSA)
22.2.1.2.2 HDR THROUGH HOMOLOGOUS RECOMBINATION (HRR)
22.2.1.2.2.1 RESOLUTION OF D-LOOP STRUCTURES
22.2.1.2.2.1.1 RESOLUTION OF D-LOOP STRUCTURES THROUGH SYNTHESIS-DEPENDENT STRAND ANNEALING (SDSA)
22.2.1.2.2.1.2 RESOLUTION OF D-LOOP STRUCTURES THROUGH HOLLIDAY JUNCTION INTERMEDIATES
22.2.1.2.2.2 HOMOLOGOUS DNA PAIRING AND STRAND EXCHANGE
22.2.1.2.2.2.1 PRESYNAPTIC PHASE OF HOMOLOGOUS DNA PAIRING AND STRAND EXCHANGE
22.2.1.2.3 PROCESSING OF DNA DOUBLE-STRAND BREAK ENDS
22.2.2 NONHOMOLOGOUS END-JOINING (NHEJ)
22.2.3 DNA DOUBLE STRAND BREAK RESPONSE
22.2.3.1 SENSING OF DNA DOUBLE STRAND BREAKS
22.2.3.2 RECRUITMENT AND ATM-MEDIATED PHOSPHORYLATION OF REPAIR AND SIGNALING PROTEINS AT DNA DOUBLE STRAND BREAKS
22.3 NUCLEOTIDE EXCISION REPAIR
22.3.1 GLOBAL GENOME NUCLEOTIDE EXCISION REPAIR (GG-NER)
22.3.1.1 DNA DAMAGE RECOGNITION IN GG-NER
22.3.1.2 FORMATION OF INCISION COMPLEX IN GG-NER
22.3.1.3 GAP-FILLING DNA REPAIR SYNTHESIS AND LIGATION IN GG-NER
22.3.1.4 DUAL INCISION IN GG-NER
22.3.2 TRANSCRIPTION-COUPLED NUCLEOTIDE EXCISION REPAIR (TC-NER)
22.3.2.1 FORMATION OF TC-NER PRE-INCISION COMPLEX
22.3.2.2 DUAL INCISION IN TC-NER
22.3.2.3 GAP-FILLING DNA REPAIR SYNTHESIS AND LIGATION IN TC-NER
22.4 FANCONI ANEMIA PATHWAY
22.5 BASE EXCISION REPAIR
22.5.1 "BASE-EXCISION REPAIR, AP SITE FORMATION"
22.5.1.1 DEPURINATION
22.5.1.1.1 RECOGNITION AND ASSOCIATION OF DNA GLYCOSYLASE WITH SITE CONTAINING AN AFFECTED PURINE
22.5.1.1.2 CLEAVAGE OF THE DAMAGED PURINE
22.5.1.2 DEPYRIMIDINATION
22.5.1.2.1 RECOGNITION AND ASSOCIATION OF DNA GLYCOSYLASE WITH SITE CONTAINING AN AFFECTED PYRIMIDINE
22.5.1.2.2 CLEAVAGE OF THE DAMAGED PYRIMIDINE
22.5.2 RESOLUTION OF ABASIC SITES (AP SITES)
22.5.2.1 DISPLACEMENT OF DNA GLYCOSYLASE BY APEX1
22.5.2.2 RESOLUTION OF AP SITES VIA THE MULTIPLE-NUCLEOTIDE PATCH REPLACEMENT PATHWAY
22.5.2.2.1 POLB-DEPENDENT LONG PATCH BASE EXCISION REPAIR
22.5.2.2.2 PCNA-DEPENDENT LONG PATCH BASE EXCISION REPAIR
22.5.2.3 RESOLUTION OF AP SITES VIA THE SINGLE-NUCLEOTIDE REPLACEMENT PATHWAY
22.5.2.3.1 ABASIC SUGAR-PHOSPHATE REMOVAL VIA THE SINGLE-NUCLEOTIDE REPLACEMENT PATHWAY
22.5.2.4 APEX1-INDEPENDENT RESOLUTION OF AP SITES VIA THE SINGLE NUCLEOTIDE REPLACEMENT PATHWAY
22.6 DNA DAMAGE BYPASS
22.6.1 TRANSLESION SYNTHESIS BY Y FAMILY DNA POLYMERASES BYPASSES LESIONS ON DNA TEMPLATE
22.6.1.1 TRANSLESION SYNTHESIS BY REV1
22.6.1.2 TRANSLESION SYNTHESIS BY POLH
22.6.1.3 TRANSLESION SYNTHESIS BY POLK
22.6.1.4 TRANSLESION SYNTHESIS BY POLI
22.6.1.5 TERMINATION OF TRANSLESION DNA SYNTHESIS
22.6.2 RECOGNITION OF DNA DAMAGE BY PCNA-CONTAINING REPLICATION COMPLEX
22.7 DNA DAMAGE REVERSAL
22.7.1 MGMT-MEDIATED DNA DAMAGE REVERSAL
22.7.2 REVERSAL OF ALKYLATION DAMAGE BY DNA DIOXYGENASES
22.7.2.1 ALKBH2 MEDIATED REVERSAL OF ALKYLATION DAMAGE
22.7.2.2 ALKBH3 MEDIATED REVERSAL OF ALKYLATION DAMAGE
23 GENE EXPRESSION (TRANSCRIPTION)
23.1 GENE SILENCING BY RNA
23.1.1 MICRORNA (MIRNA) BIOGENESIS
23.1.2 SMALL INTERFERING RNA (SIRNA) BIOGENESIS
23.1.3 POST-TRANSCRIPTIONAL SILENCING BY SMALL RNAS
23.1.4 TRANSCRIPTIONAL REGULATION BY SMALL RNAS
23.1.5 PIWI-INTERACTING RNA (PIRNA) BIOGENESIS
23.2 EPIGENETIC REGULATION OF GENE EXPRESSION
23.2.1 PRC2 METHYLATES HISTONES AND DNA
23.2.2 "TET1,2,3 AND TDG DEMETHYLATE DNA"
23.2.3 POSITIVE EPIGENETIC REGULATION OF RRNA EXPRESSION
23.2.3.1 ERCC6 (CSB) AND EHMT2 (G9A) POSITIVELY REGULATE RRNA EXPRESSION
23.2.3.2 B-WICH COMPLEX POSITIVELY REGULATES RRNA EXPRESSION
23.2.4 NEGATIVE EPIGENETIC REGULATION OF RRNA EXPRESSION
23.2.4.1 SIRT1 NEGATIVELY REGULATES RRNA EXPRESSION
23.2.4.2 NORC NEGATIVELY REGULATES RRNA EXPRESSION
23.2.5 DNA METHYLATION
23.3 RNA POLYMERASE II TRANSCRIPTION
23.3.1 GENERIC TRANSCRIPTION PATHWAY
23.3.1.1 YAP1- AND WWTR1 (TAZ)-STIMULATED GENE EXPRESSION
23.3.1.2 TRANSCRIPTIONAL ACTIVITY OF SMAD2/SMAD3:SMAD4 HETEROTRIMER
23.3.1.2.1 DOWNREGULATION OF SMAD2/3:SMAD4 TRANSCRIPTIONAL ACTIVITY
23.3.1.2.2 SMAD2/SMAD3:SMAD4 HETEROTRIMER REGULATES TRANSCRIPTION
23.3.1.3 NOTCH-HLH TRANSCRIPTION PATHWAY
23.3.1.4 TRANSCRIPTIONAL REGULATION BY TP53
23.3.1.4.1 TP53 REGULATES METABOLIC GENES
23.3.1.4.2 REGULATION OF TP53 ACTIVITY
23.3.1.4.2.1 REGULATION OF TP53 ACTIVITY THROUGH PHOSPHORYLATION
23.3.1.4.2.2 REGULATION OF TP53 ACTIVITY THROUGH ACETYLATION
23.3.1.4.2.2.1 PI5P REGULATES TP53 ACETYLATION
23.3.1.4.2.3 REGULATION OF TP53 ACTIVITY THROUGH ASSOCIATION WITH CO-FACTORS
23.3.1.4.2.4 REGULATION OF TP53 ACTIVITY THROUGH METHYLATION
23.3.1.4.2.5 REGULATION OF TP53 EXPRESSION AND DEGRADATION
23.3.1.4.2.5.1 REGULATION OF TP53 EXPRESSION
23.3.1.4.2.5.2 REGULATION OF TP53 DEGRADATION
23.3.1.4.3 TP53 REGULATES TRANSCRIPTION OF CELL DEATH GENES
23.3.1.4.3.1 TP53 REGULATES TRANSCRIPTION OF GENES INVOLVED IN CYTOCHROME C RELEASE
23.3.1.4.3.2 TP53 REGULATES TRANSCRIPTION OF SEVERAL ADDITIONAL CELL DEATH GENES WHOSE SPECIFIC ROLES IN P53-DEPENDENT APOPTOSIS REMAIN UNCERTAIN
23.3.1.4.3.3 TP53 REGULATES TRANSCRIPTION OF CASPASE ACTIVATORS AND CASPASES
23.3.1.4.3.4 TP53 REGULATES TRANSCRIPTION OF DEATH RECEPTORS AND LIGANDS
23.3.1.4.4 TP53 REGULATES TRANSCRIPTION OF CELL CYCLE GENES
23.3.1.4.4.1 TP53 REGULATES TRANSCRIPTION OF GENES INVOLVED IN G2 CELL CYCLE ARREST
23.3.1.4.4.2 TP53 REGULATES TRANSCRIPTION OF ADDITIONAL CELL CYCLE GENES WHOSE EXACT ROLE IN THE P53 PATHWAY REMAIN UNCERTAIN
23.3.1.4.4.3 TP53 REGULATES TRANSCRIPTION OF GENES INVOLVED IN G1 CELL CYCLE ARREST
23.3.1.4.5 TP53 REGULATES TRANSCRIPTION OF DNA REPAIR GENES
23.3.1.5 NUCLEAR RECEPTOR TRANSCRIPTION PATHWAY
23.3.1.6 TRANSCRIPTIONAL REGULATION BY THE AP-2 (TFAP2) FAMILY OF TRANSCRIPTION FACTORS
23.3.1.6.1 NEGATIVE REGULATION OF ACTIVITY OF TFAP2 (AP-2) FAMILY TRANSCRIPTION FACTORS
23.3.1.6.2 TFAP2 (AP-2) FAMILY REGULATES TRANSCRIPTION OF OTHER TRANSCRIPTION FACTORS
23.3.1.6.3 ACTIVATION OF THE TFAP2 (AP-2) FAMILY OF TRANSCRIPTION FACTORS
23.3.1.6.4 TFAP2 (AP-2) FAMILY REGULATES TRANSCRIPTION OF GROWTH FACTORS AND THEIR RECEPTORS
23.3.1.6.5 TFAP2 (AP-2) FAMILY REGULATES TRANSCRIPTION OF CELL CYCLE FACTORS
23.3.1.6.6 TFAP2A ACTS AS A TRANSCRIPTIONAL REPRESSOR DURING RETINOIC ACID INDUCED CELL DIFFERENTIATION
23.3.1.7 TRANSCRIPTIONAL REGULATION BY RUNX3
23.3.1.7.1 RUNX3 REGULATES CDKN1A TRANSCRIPTION
23.3.1.7.2 RUNX3 REGULATES NOTCH SIGNALING
23.3.1.7.3 REGULATION OF RUNX3 EXPRESSION AND ACTIVITY
23.3.1.7.4 RUNX3 REGULATES IMMUNE RESPONSE AND CELL MIGRATION
23.3.1.7.5 RUNX3 REGULATES WNT SIGNALING
23.3.1.7.6 RUNX3 REGULATES YAP1-MEDIATED TRANSCRIPTION
23.3.1.7.7 RUNX3 REGULATES RUNX1-MEDIATED TRANSCRIPTION
23.3.1.7.8 RUNX3 REGULATES P14-ARF
23.3.1.7.9 RUNX3 REGULATES BCL2L11 (BIM) TRANSCRIPTION
23.3.1.8 TRANSCRIPTIONAL REGULATION BY RUNX2
23.3.1.8.1 REGULATION OF RUNX2 EXPRESSION AND ACTIVITY
23.3.1.8.2 RUNX2 REGULATES BONE DEVELOPMENT
23.3.1.8.2.1 RUNX2 REGULATES OSTEOBLAST DIFFERENTIATION
23.3.1.8.2.2 RUNX2 REGULATES CHONDROCYTE MATURATION
23.3.1.8.3 RUNX2 REGULATES GENES INVOLVED IN CELL MIGRATION
23.3.1.8.4 RUNX2 REGULATES GENES INVOLVED IN DIFFERENTIATION OF MYELOID CELLS
23.3.1.9 TRANSCRIPTIONAL REGULATION BY RUNX1
23.3.1.9.1 RUNX1 AND FOXP3 CONTROL THE DEVELOPMENT OF REGULATORY T LYMPHOCYTES (TREGS)
23.3.1.9.2 RUNX1 REGULATES ESTROGEN RECEPTOR MEDIATED TRANSCRIPTION
23.3.1.9.3 REGULATION OF RUNX1 EXPRESSION AND ACTIVITY
23.3.1.9.4 RUNX1 REGULATES EXPRESSION OF COMPONENTS OF TIGHT JUNCTIONS
23.3.1.9.5 RUNX1 REGULATES GENES INVOLVED IN MEGAKARYOCYTE DIFFERENTIATION AND PLATELET FUNCTION
23.3.1.9.6 RUNX1 REGULATES TRANSCRIPTION OF GENES INVOLVED IN DIFFERENTIATION OF HSCS
23.3.1.9.7 RUNX1 REGULATES TRANSCRIPTION OF GENES INVOLVED IN DIFFERENTIATION OF KERATINOCYTES
23.3.1.9.8 RUNX1 INTERACTS WITH CO-FACTORS WHOSE PRECISE EFFECT ON RUNX1 TARGETS IS NOT KNOWN
23.3.1.9.9 RUNX1 REGULATES TRANSCRIPTION OF GENES INVOLVED IN BCR SIGNALING
23.3.1.9.10 RUNX1 REGULATES TRANSCRIPTION OF GENES INVOLVED IN DIFFERENTIATION OF MYELOID CELLS
23.3.1.9.11 RUNX1 REGULATES TRANSCRIPTION OF GENES INVOLVED IN INTERLEUKIN SIGNALING
23.3.1.9.12 RUNX1 REGULATES TRANSCRIPTION OF GENES INVOLVED IN WNT SIGNALING
23.3.1.10 TRANSCRIPTIONAL REGULATION BY E2F6
23.3.1.11 TRANSCRIPTIONAL REGULATION BY MECP2
23.3.1.11.1 REGULATION OF MECP2 EXPRESSION AND ACTIVITY
23.3.1.11.2 MECP2 REGULATES NEURONAL RECEPTORS AND CHANNELS
23.3.1.11.3 MECP2 REGULATES TRANSCRIPTION OF NEURONAL LIGANDS
23.3.1.11.4 MECP2 REGULATES TRANSCRIPTION FACTORS
23.3.1.11.5 MECP2 REGULATES TRANSCRIPTION OF GENES INVOLVED IN GABA SIGNALING
23.3.1.12 FOXO-MEDIATED TRANSCRIPTION
23.3.1.12.1 REGULATION OF LOCALIZATION OF FOXO TRANSCRIPTION FACTORS
23.3.1.12.2 FOXO-MEDIATED TRANSCRIPTION OF CELL DEATH GENES
23.3.1.12.3 "FOXO-MEDIATED TRANSCRIPTION OF OXIDATIVE STRESS, METABOLIC AND NEURONAL GENES"
23.3.1.12.4 REGULATION OF FOXO TRANSCRIPTIONAL ACTIVITY BY ACETYLATION
23.3.1.12.5 FOXO-MEDIATED TRANSCRIPTION OF CELL CYCLE GENES
23.3.2 RNA POLYMERASE II PRE-TRANSCRIPTION EVENTS
23.3.3 RNA POLYMERASE II TRANSCRIBES SNRNA GENES
23.3.4 RNA POLYMERASE II TRANSCRIPTION PRE-INITIATION AND PROMOTER OPENING
23.3.5 RNA POLYMERASE II TRANSCRIPTION TERMINATION
23.3.5.1 CLEAVAGE OF GROWING TRANSCRIPT IN THE TERMINATION REGION
23.3.6 RNA POLYMERASE II TRANSCRIPTION ELONGATION
23.3.6.1 FORMATION OF RNA POL II ELONGATION COMPLEX
23.3.6.2 FORMATION OF THE EARLY ELONGATION COMPLEX
23.3.7 RNA POLYMERASE II TRANSCRIPTION INITIATION AND PROMOTER CLEARANCE
23.3.7.1 RNA POLYMERASE II PROMOTER ESCAPE
23.3.7.2 RNA POLYMERASE II TRANSCRIPTION INITIATION
23.3.8 RNA POL II CTD PHOSPHORYLATION AND INTERACTION WITH CE
23.4 RNA POLYMERASE I TRANSCRIPTION
23.4.1 RNA POLYMERASE I CHAIN ELONGATION
23.4.2 RNA POLYMERASE I PROMOTER CLEARANCE
23.4.2.1 RNA POLYMERASE I PROMOTER OPENING
23.4.2.2 RNA POLYMERASE I TRANSCRIPTION INITIATION
23.4.2.3 RNA POLYMERASE I PROMOTER ESCAPE
23.4.3 RNA POLYMERASE I TRANSCRIPTION TERMINATION
23.5 RNA POLYMERASE III TRANSCRIPTION
23.5.1 RNA POLYMERASE III CHAIN ELONGATION
23.5.2 RNA POLYMERASE III TRANSCRIPTION TERMINATION
23.5.3 RNA POLYMERASE III ABORTIVE AND RETRACTIVE INITIATION
23.5.4 RNA POLYMERASE III TRANSCRIPTION INITIATION
23.5.4.1 RNA POLYMERASE III TRANSCRIPTION INITIATION FROM TYPE 1 PROMOTER
23.5.4.2 RNA POLYMERASE III TRANSCRIPTION INITIATION FROM TYPE 2 PROMOTER
23.5.4.3 RNA POLYMERASE III TRANSCRIPTION INITIATION FROM TYPE 3 PROMOTER
23.6 TRANSCRIPTION FROM MITOCHONDRIAL PROMOTERS
23.6.1 MITOCHONDRIAL TRANSCRIPTION INITIATION
23.6.2 MITOCHONDRIAL TRANSCRIPTION TERMINATION
24 METABOLISM OF RNA
24.1 METABOLISM OF NON-CODING RNA
24.1.1 SNRNP ASSEMBLY
24.2 INSULIN-LIKE GROWTH FACTOR-2 MRNA BINDING PROTEINS (IGF2BPS/IMPS/VICKZS) BIND RNA
24.3 DEADENYLATION-DEPENDENT MRNA DECAY
24.3.1 DEADENYLATION OF MRNA
24.3.2 MRNA DECAY BY 3' TO 5' EXORIBONUCLEASE
24.3.3 MRNA DECAY BY 5' TO 3' EXORIBONUCLEASE
24.4 REGULATION OF MRNA STABILITY BY PROTEINS THAT BIND AU-RICH ELEMENTS
24.4.1 BUTYRATE RESPONSE FACTOR 1 (BRF1) BINDS AND DESTABILIZES MRNA
24.4.2 AUF1 (HNRNP D0) BINDS AND DESTABILIZES MRNA
24.4.3 "TRISTETRAPROLIN (TTP, ZFP36) BINDS AND DESTABILIZES MRNA"
24.4.4 HUR (ELAVL1) BINDS AND STABILIZES MRNA
24.4.5 KSRP (KHSRP) BINDS AND DESTABILIZES MRNA
24.5 MRNA CAPPING
24.6 PROCESSING OF CAPPED INTRON-CONTAINING PRE-MRNA
24.6.1 MRNA SPLICING
24.6.1.1 MRNA SPLICING - MAJOR PATHWAY
24.6.1.2 MRNA SPLICING - MINOR PATHWAY
24.6.2 MRNA 3'-END PROCESSING
24.6.3 TRANSPORT OF MATURE TRANSCRIPT TO CYTOPLASM
24.6.3.1 TRANSPORT OF MATURE MRNAS DERIVED FROM INTRONLESS TRANSCRIPTS
24.6.3.1.1 TRANSPORT OF THE SLBP INDEPENDENT MATURE MRNA
24.6.3.1.2 TRANSPORT OF THE SLBP DEPENDANT MATURE MRNA
24.6.3.1.3 TRANSPORT OF MATURE MRNA DERIVED FROM AN INTRONLESS TRANSCRIPT
24.6.3.2 TRANSPORT OF MATURE MRNA DERIVED FROM AN INTRON-CONTAINING TRANSCRIPT
24.7 TRNA PROCESSING
24.7.1 TRNA MODIFICATION IN THE NUCLEUS AND CYTOSOL
24.7.1.1 SYNTHESIS OF WYBUTOSINE AT G37 OF TRNA(PHE)
24.7.2 TRNA PROCESSING IN THE NUCLEUS
24.7.3 TRNA PROCESSING IN THE MITOCHONDRION
24.7.4 TRNA MODIFICATION IN THE MITOCHONDRION
24.8 RRNA PROCESSING
24.8.1 RRNA PROCESSING IN THE MITOCHONDRION
24.8.1.1 RRNA MODIFICATION IN THE MITOCHONDRION
24.8.2 RRNA PROCESSING IN THE NUCLEUS AND CYTOSOL
24.8.2.1 RRNA MODIFICATION IN THE NUCLEUS AND CYTOSOL
24.8.2.2 MAJOR PATHWAY OF RRNA PROCESSING IN THE NUCLEOLUS AND CYTOSOL
24.9 PROCESSING OF CAPPED INTRONLESS PRE-MRNA
24.9.1 SLBP INDEPENDENT PROCESSING OF HISTONE PRE-MRNAS
24.9.2 SLBP DEPENDENT PROCESSING OF REPLICATION-DEPENDENT HISTONE PRE-MRNAS
24.9.3 PROCESSING OF INTRONLESS PRE-MRNAS
24.1 MRNA EDITING
24.10.1 MRNA EDITING: C TO U CONVERSION
24.10.1.1 FORMATION OF THE EDITOSOME
24.10.2 MRNA EDITING: A TO I CONVERSION
24.10.2.1 C6 DEAMINATION OF ADENOSINE
24.10.2.2 FORMATION OF EDITOSOMES BY ADAR PROTEINS
24.11 NONSENSE-MEDIATED DECAY (NMD)
24.11.1 NONSENSE MEDIATED DECAY (NMD) INDEPENDENT OF THE EXON JUNCTION COMPLEX (EJC)
24.11.2 NONSENSE MEDIATED DECAY (NMD) ENHANCED BY THE EXON JUNCTION COMPLEX (EJC)
25 CELLULAR RESPONSES TO EXTERNAL STIMULI
25.1 MACROAUTOPHAGY
25.2 CELLULAR RESPONSES TO STRESS
25.2.1 CELLULAR RESPONSE TO HYPOXIA
25.2.1.1 REGULATION OF HYPOXIA-INDUCIBLE FACTOR (HIF) BY OXYGEN
25.2.1.1.1 REGULATION OF GENE EXPRESSION BY HYPOXIA-INDUCIBLE FACTOR
25.2.1.1.2 OXYGEN-DEPENDENT ASPARAGINE HYDROXYLATION OF HYPOXIA-INDUCIBLE FACTOR ALPHA
25.2.1.1.3 OXYGEN-DEPENDENT PROLINE HYDROXYLATION OF HYPOXIA-INDUCIBLE FACTOR ALPHA
25.2.2 CELLULAR SENESCENCE
25.2.2.1 OXIDATIVE STRESS INDUCED SENESCENCE
25.2.2.2 SENESCENCE-ASSOCIATED SECRETORY PHENOTYPE (SASP)
25.2.2.3 ONCOGENE INDUCED SENESCENCE
25.2.2.4 DNA DAMAGE/TELOMERE STRESS INDUCED SENESCENCE
25.2.2.4.1 FORMATION OF SENESCENCE-ASSOCIATED HETEROCHROMATIN FOCI (SAHF)
25.2.3 DETOXIFICATION OF REACTIVE OXYGEN SPECIES
25.2.4 HSP90 CHAPERONE CYCLE FOR STEROID HORMONE RECEPTORS (SHR)
25.2.5 CELLULAR RESPONSE TO HEAT STRESS
25.2.5.1 REGULATION OF HSF1-MEDIATED HEAT SHOCK RESPONSE
25.2.5.2 HSF1 ACTIVATION
25.2.5.3 HSF1-DEPENDENT TRANSACTIVATION
25.2.5.3.1 ATTENUATION PHASE
25.3 RESPONSE TO METAL IONS
25.3.1 MTF1 ACTIVATES GENE EXPRESSION
25.3.2 METALLOTHIONEINS BIND METALS
26 DIGESTION AND ABSORPTION
26.1 DIGESTION
26.1.1 DIGESTION OF DIETARY CARBOHYDRATE
26.1.2 DIGESTION OF DIETARY LIPID
26.2 INTESTINAL ABSORPTION
26.2.1 INTESTINAL LIPID ABSORPTION
26.2.2 INTESTINAL HEXOSE ABSORPTION
27 PROTEIN LOCALIZATION
27.1 MITOCHONDRIAL PROTEIN IMPORT
27.2 PEROXISOMAL PROTEIN IMPORT
27.2.1 TYSND1 CLEAVES PEROXISOMAL PROTEINS
